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Discovery of HDL subspecies and investigation of their associations with  
insulin sensitivity and early carotid atherosclerosis 
 
 
Abstract 
 
Recent findings from genome-wide association studies and pharmaceutical trials of CETP 
inhibitors suggest that HDL cholesterol might not fully capture the anti-atherogenic functions of 
HDL. The protein component of HDL might be more informative in explaining HDL functions 
because proteins have characteristics that can modify the biological properties of HDL. 
 
In Chapter 1, I examined whether some proteins located in the HDL size or density range by 
proteomics studies were present in distinct apoA-I HDL subspecies that could be identified and 
quantified by a novel sandwich ELISA. Known HDL subspecies containing apoA-II, apoC-III 
and apoE comprised 70%, 6% and 10%, respectively, and found that novel HDL subspecies 
containing apoC-I, apoJ, alpha-1 antitrypsin, plasminogen, and apoC-II comprised 14%, 7%, 5%, 
3% and 1%, respectively, of the total apoA-I in HDL.  
 
HDL that contains apoC-III has been associated with a higher prevalence of obesity and an 
elevated risk of CHD, opposite to what has been seen for HDL that does not contain apoC-III. To 
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further our knowledge on apoC-III-based HDL subspecies, I investigated their associations with 
insulin sensitivity measured by oral glucose tolerance test (OGTT) in Chapter 2 and early stages 
of carotid atherosclerosis measured as carotid intima-media thickness (cIMT) in Chapter 3. 
Using the novel sandwich ELISA established in Chapter 1, I measured the concentrations of 
apoA-I in HDL with and without apoC-III in the European multi-center “Relationship between 
Insulin Sensitivity and Cardiovascular disease” (RISC) study.  
 
ApoA-I in HDL with and without apoC-III demonstrated significantly opposite associations with 
both 3-year change in insulin sensitivity and cIMT at baseline. ApoA-I with apoC-III was 
associated with a decrease in insulin sensitivity and higher cIMT, whereas the concentration of 
apoA-I without apoC-III was associated with an increase in insulin sensitivity and lower cIMT. 
The results for apoC-III itself in HDL was consistent with apoA-I with apoC-III. Total apoA-I 
was null in both cases. These findings suggest that the presence of apoC-III on HDL diminishes 
and impairs otherwise beneficial effects of HDL on glucose regulation and atheroprotection, and 
support the potential of HDL apoC-III as a promising target for diabetes and atherosclerosis 
prevention and treatment.  
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ABSTRACT 
 
Background 
HDL is a heterogeneous group of lipoproteins comprised of a variety of proteins with distinct 
functions and associations with CVD. We hypothesized that some of the proteins located in the 
HDL size or density range by proteomics studies are present in distinct apoA-I HDL subspecies 
that can be identified and quantified by a novel sandwich ELISA. 
 
Methods 
A microplate coated with antibody against a protein of interest that separates the plasma 
lipoproteins into bound and unbound fractions. Each fraction is transferred to an anti-apoA-I 
antibody coated microplate to measure the concentrations of apoA-I with and without the 
protein.  
 
Findings 
We confirmed that known HDL subspecies containing apoA-II, apoC-III and apoE comprised 
70%, 6% and 10%, respectively, and found that novel HDL subspecies containing apoC-I, apoJ, 
alpha-1 antitrypsin, plasminogen, and apoC-II comprised 14%, 7%, 5%, 3% and 1%, 
respectively, of the total apoA-I in HDL.  
 
Conclusion 
We established a novel sandwich ELISA, which demonstrated the existence of eight apoA-I 
HDL subspecies and showed that they exist in abundance with potential biological importance. 
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The method is suitable for studying HDL subspecies in relation to dyslipidemia, CVD risk and 
treatments, and is also applicable to apoB lipoprotein subspecies. 
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INTRODUCTION 
The protective effect of HDL-cholesterol is challenged by pharmaceutical trials of 
CETP inhibitors and genome-wide association studies, which suggest that HDL-cholesterol may 
not be a suitable therapeutic target because it may not represent HDL function. The protein 
composition of HDL may be more relevant than HDL-cholesterol to the risk of CVD because 
proteins have specific functions that they may impart to HDL. Alaupovic first proposed in 1964 
the concept of classifying lipoprotein subspecies on the basis of the protein components of the 
lipoprotein particles instead of the lipid component and the size (1). Two groups independently 
demonstrated the concept of HDL subspecies by different immunochemical techniques (2, 3). 
About two thirds of plasma apoA-I in normolipidemic people is on HDL that also has apoA-II 
while the rest of apoA-I is on HDL that is free of apoA-II (4-6). Recently we found that HDL 
exists in subspecies based on the apoC-III and apoE content and that about 6-7% of the total 
plasma apoA-I in HDL is associated with apoC-III or apoE in people with normal body weight 
(7). Moreover, in HDL particles associated with apoC-III, there are on average 4 molecules of 
apoC-III per apoA-I molecule present in the HDL particles. Assuming an average of 4 molecules 
of apoA-I per HDL particle (8), an HDL that has apoC-III has 16 molecules of it. This is more 
than enough apoC-III to be present on all HDL particles. A similar calculation can be made for 
HDL that contains apoE (7). These observations indicate that proteins cluster into certain HDL 
particles and form subspecies rather than being distributed throughout all HDL particles in 
plasma. 
The classification of HDL into subspecies based on the presence or absence of protein 
components has clinical significance. The percentage of apoA-I HDL that contains apoC-III or 
apoE in people with obesity was about 13-14%, which is doubled as compared to people with 
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normal weight (7). Moreover, HDL without apoC-III was associated with decreased risk of 
CVD, whereas HDL with apoC-III was associated with increased risk of CVD (9). Of note, the 
apoC-III concentration in HDL was not significantly associated with CVD. These findings 
suggest that the concentration of HDL particles with any apoC-III may be more relevant with 
regard to CVD risk than how much apoC-III is contained in HDL.  
Over the past decade, HDL proteomics studies have identified many proteins located in 
HDL (10-25). Davidson has compiled a list of these HDL proteins 
(http://homepages.uc.edu/~davidswm/HDLproteome.html), designating 95 as likely based on the 
criteria of appearing in 3 separate reports from 3 independent laboratories. The properties of the 
HDL associated proteins include not only lipid metabolism and transport but also complement 
regulation, inflammation or acute-phase response, anti-oxidation and anti-thrombosis, hemostasis 
and protease inhibition.  
There is increasing evidence that HDL particles are compositionally heterogeneous. For 
example, Davidson and colleagues identified the existence of distinct protein clusters in HDL 
particles and suggested the presence of HDL particle subpopulations each with distinct protein 
components (15, 16). While it has been shown by immunoaffinity chromatography that apoA-II, 
apoC-III and apoE define apoA-I-containing HDL subspecies (4, 7), it is yet unknown whether 
other proteins located in the HDL size or density range by proteomics also constitute apoA-I-
containing HDL subspecies.  
Therefore, we hypothesized that some of the proteins identified in proteomics studies 
are present in distinct apoA-I HDL subspecies that can be identified and quantified by a novel 
sandwich ELISA. Immunoaffinity chromatography has been used as a standard method to 
characterize lipoprotein particles based on the protein content but it is time-consuming and 
6 
 
 
impractical for large population studies. In order to determine which proteins constitute 
subspecies of HDL and to measure the apoA-I concentrations of HDL subspecies, we established 
a novel sandwich ELISA that is faster and more reproducible than immunoaffinity 
chromatography. We selected eight proteins with varied functions as shown in Table 1-1. In 
addition to apoA-II, apoC-III, and apoE, which define known subspecies of apoA-I HDL (4, 7), 
we also selected apoC-I, apoC-II, apoJ, alpha-1 antitrypsin (A1AT) and plasminogen, to 
determine whether their association with HDL constitutes new subspecies of apoA-I HDL, and in 
what concentrations they exist. We confirmed the presence and concentrations of the three 
known subspecies, and then found that the 5 others were in subspecies using the novel sandwich 
ELISA. Most of them comprise 5% or more of total apoA-I.  
 
MATERIALS AND METHODS 
Blood samples 
23 healthy male and female volunteers aged 23 to 64 were recruited from students and 
staff at Harvard T. H. Chan School of Public Health to create plasma pools. They were asked to 
fast the night before and up until the blood draw. Blood samples were collected in EDTA-treated 
tubes, centrifuged, divided into aliquots and stored at -80°C. After blood draw, the plasma samples 
were immediately anonymized. All volunteers gave informed consent.  
 
Measurement of Lipids and Reference Apolipoprotein Levels in HDL subspecies 
The 23 individual samples were removed from cryogenic storage and thawed at room 
temperature. ApoA-I was measured in whole plasma by standard sandwich ELISA, and 
cholesterol and triglycerides were measured by enzymatic methods (Infinity Kit, Thermo Fisher 
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Scientific, Waltham, MA). Based on the content of lipids and apolipoproteins, the 23 individual 
samples were placed into four groups and those in the same group were combined into one pool: 
high triglyceride/low HDL cholesterol group (Pool 1), high LDL cholesterol group (Pool 2), high 
apoA-I group (Pool 3), and low triglyceride/low LDL cholesterol group (Pool 4). After the pools 
were created, apoA-I, apoB, cholesterol and triglycerides were measured in the four pools.  
For assessing the validity of the novel sandwich ELISA against a validated method, we 
performed immunoaffinity chromatography to obtain reference levels of the four plasma pools 
for their concentrations of total apoC-III, apoA-I that is associated with apoC-III and apoA-I that 
is not associated with apoC-III. Each pool was filtered, and the filtered plasma was loaded into 
20 ml Econo-Pac columns (Bio-Rad Laboratories, Hercules, CA) packed with anti–apoC-III 
resin (Sepharose 4B Resin; Academy Biomedical Company Inc, Houston, TX). Plasma and resin 
were incubated for 16 hours at 4°C with mixing. The unbound fraction was eluted from the 
column by gravity followed by washing three times with 4 ml 1x phosphate-buffered saline 
(PBS). The bound fraction was then eluted from the columns three times with 4 ml 3 mol/l 
sodium thiocyanate in 1xPBS, followed by washing once with 3 ml PBS and was immediately 
desalted with the use of concentrators (Spin-X UF Concentrator, Corning). The unbound fraction 
was measured for the concentration of apoA-I that is not associated with apoC-III, and the bound 
fraction for the concentration of apoA-I that is associated with apoC-III by standard sandwich 
ELISA.  
For testing the specificity of the novel sandwich ELISA, plasma from three of the 23 
individual donors was selected based on the concentration of apoA-I with apoC-III as determined 
by immunoaffinity chromatography. These three participants were selected to represent low, 
medium and high levels of apoA-I with apoC-III and were named Participant 1, 2 and 3, 
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respectively.  
 
Measuring apoA-I concentrations of HDL subspecies using the novel sandwich ELISA 
We use apoC-III as an example to describe the assay for the apoA-I concentration that is 
associated with or without apoC-III (Figure 1-1). A 96-well microplate (Greiner Bio-One 
MICROLON™ 600, VWR Cat #82050-734) was coated with rabbit anti-human apoC-III 
antibody (Academy Biomedical, Cat #33A-R1b, 10 μg/ml in 1xPBS) to be used as the first plate 
(apoC-III plate). Two microplates were coated with goat anti-human apoA-I antibody (Academy 
Biomedical, Cat #11A-G2b, 5 μg/ml in 1xPBS) to be used as the second and third plates (apoA-I 
without apoC-III plate and apoA-I with apoC-III plate). The apoC-III plate facilitates the 
fractionation of lipoproteins by apoC-III content and quantifies plasma total apoC-III 
concentration, the apoA-I without apoC-III plate quantifies the apoA-I concentration of HDL 
that is not associated with apoC-III, and the apoA-I with apoC-III plate quantifies the apoA-I 
concentration of HDL that is associated with apoC-III. The plates were incubated for 1 hour at 
37°C and washed three times with 300 μl washing buffer (0.1% Tween 20 in 1xPBS). Then the 
plates were blocked with blocking buffer (Pierce, Casein in 1xPBS (1% w/v) for 1 hour at 37°C, 
VWR Cat #PI37528) followed by washing three times with 300 μl washing buffer. 
A plasma pool whose apoC-III and apoA-I concentrations had been previously established to 
be 11.5 mg/dl and 174.0 mg/dl, respectively was chosen to produce a calibration curve. The 
calibration curve was prepared in dilutions starting at 10,000x and serially 2x further to 640,000x 
in 1xPBS containing 0.5% BSA. Four pooled plasma samples were prepared at 1:50,000 
dilutions. The diluent did not contain Tween 20 so that the lipoprotein particle remained intact 
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without delipidation. The prepared calibration curve and pooled samples were put in the apoC-III 
plate and incubated overnight at 4°C.  
On Day2, the unbound fraction that did not have apoC-III was transferred from the apoC-III 
plate to the apoA-I without apoC-III plate. It was mixed well with Tween-containing diluent 
(1xPBS/2% BSA/0.05% Tween 20). This step was to dilute the unbound fraction to levels that 
fall within the calibration range. The apoA-I without apoC-III plate was then incubated for 1 
hour at 37°C. After transferring the unbound fraction to the apoA-I without apoC-III plate, the 
apoC-III plate was washed three times gently with 1xPBS and the lipid and protein components 
of the bound lipoproteins on the apoC-III plate were dissociated from anti apoC-III antibody on 
the plate by Tween-containing diluent incubated for 1 hour at room temperature on the orbital 
shaker. The dissociated fraction was transferred from the apoC-III plate to a third plate, apoA-I 
with apoC-III plate that was coated with anti-apoA-I antibody, and incubated for 2 hours at 
37°C. 
After these steps, all three plates were washed three times with washing buffer. Horseradish 
peroxidase (HRP) conjugated anti-apoC-III antibody (Academy Biomedical, Cat #33H-G2b, 1 
μg/ml in 1xPBS) was added to the apoC-III plate and HRP conjugated anti-apoA-I antibody 
(Academy Biomedical, Cat #11H-G1b, 1 μg/ml in 1xPBS) was added to the apoA-I without 
apoC-III plate before incubation for 1 hour at 37°C. Following washing three times with 
washing buffer, o-phenylenediamine (OPD) (Sigma Aldrich, Cat #P9187-50SET) was added to 
each well on both the apoC-III and apoA-I without apoC-III plates to develop color for 1 hour 
and 20 minutes at room temperature and the absorbance was read at 450 nm. For the apoA-I with 
apoC-III plate, biotinylated anti-apoA-I antibody (Academy Biomedical, Cat #11B-G2b, 1 μg/ml 
with 1xPBS) was added, incubated for 1 hour at 37°C, washed three times with washing buffer, 
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followed by addition of avidin peroxidase (Sigma Aldrich, Cat #A7419-2ML, 0.01 μg/ml in 
1xPBS), and incubated for 1 hour at 37°C. After washing three times with washing buffer, OPD 
was added and incubated for 1 hour and 20 minutes before the absorbance was read at 450nm. 
Each sample was measured in triplicate. The percentage of apoA-I that has apoC-III was 
calculated by dividing the concentration of apoA-I with apoC-III (the apoA-I with apoC-III 
plate) by the concentration of total apoA-I (the sum of the apoA-I without apoC-III and apoA-I 
with apoC-III plates).  
Assays for other HDL subspecies were performed similarly. We also developed an assay for 
apoB with and without apoC-III by applying the same principle. The sources of coating 
antibodies and detection antibodies used for each assay are described in Supplementary Table 1-
1.  
 
RESULTS 
Pooled samples characteristics 
Characteristics of lipid and reference apolipoprotein levels of the four pooled samples are 
shown in Table 1-2.  
 
Sensitivity and specificity 
Our modified sandwich ELISA was demonstrated to be very sensitive. The absorbance 
decreased dose-dependently as the dilutions increased from 10,000x serially 2x up to 640,000x 
for all the three measures: total apoC-III, apoA-I without apoC-III and apoA-I with apoC-III 
(Figure 1-2). The lower limit of quantification for ELISA was established at 0.018 μg/dl for 
apoC-III, 0.026 μg/dl for apoA-I without apoC-III, and 0.159 μg/dl for apoA-I with apoC-III. 
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To assess the specificity of the newly developed ELISA, plasma samples depleted of 
apoC-III by immunoaffinity chromatography were measured for content of apoC-III and of 
apoA-I with and without apoC-III using the modified sandwich ELISA. For comparison, an 
apoC-III undepleted (unaltered) plasma sample was measured as well. For this experiment, we 
used three individual plasma samples from Participants 1, 2 and 3, who had low, medium and 
high levels, respectively, of apoA-I with apoC-III determined by immunoaffinity 
chromatography. Plasma apoC-III was detected only in the undepleted samples (Figure 1-3A). 
Both apoC-III depleted and undepleted samples showed absorbance on the apoA-I without apoC-
III plate (Figure 1-3B). The concentration of apoA-I without apoC-III was 20-25% lower in the 
depleted sample as compared to the unaltered sample, which is likely due to loss during 
immunoaffinity chromatography. The plasma depleted of apoC-III showed no absorbance on the 
apoA-I with apoC-III plate, indicating a good specificity, while the undepleted sample showed 
absorbance in a concentration-dependent manner (Figure 1-3C).  
 
Validity 
To evaluate the validity of the assay against a validated method, we compared the 
concentrations of apoC-III and apoA-I with and without apoC-III obtained from the modified 
sandwich ELISA with the reference levels determined by immunoaffinity chromatography. The 
correlations between the values obtained by ELISA and the ones determined by immunoaffinity 
chromatography were 0.96 for apoC-III, 0.91 for apoA-I without apoC-III, and 0.89 for apoA-I 
with apoC-III (Figure 1-4A). The mean values obtained by our novel ELISA method compared 
to the reference values determined by immunoaffinity chromatography are shown in Figure 1-
4B.  
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Reproducibility 
Reproducibility within an assay (intra-assay CV%) and between assays (inter-assay 
CV%) was compared between the modified sandwich ELISA and immunoaffinity chromatography 
(Table 1-3).  
The modified sandwich ELISA had lower intra-assay CV% than immunoaffinity 
chromatography. The inter-assay CV% from ELISA was substantially lower than that from 
immunoaffinity chromatography, particularly for apoC-III and apoA-I with apoC-III. Thus, ELISA 
had consistently better reproducibility both within an assay and between assays than 
immunoaffinity chromatography.   
 
Other proteins associated with apoA-I HDL  
We quantified the concentrations of eight HDL subspecies each containing either apoA-
II, apoC-III, apoE, apoC-I, apoC-II, apoJ, A1AT, or plasminogen. The mean values of the four 
pools and the percentage of apoA-I HDL that was associated with each protein are shown in 
Figure 1-5A. Out of the total apoA-I concentration of 147 mg/dl, the majority of ApoA-I was 
found to be associated with apoA-II; 70% of apoA-I (mean ± SD: 102 ± 26 mg/dl) had apoA-II, 
whereas the remaining 30% of apoA-I was apoA-II free. 10% of apoA-I (14 ± 2 mg/dl) was 
associated with apoE, and 6% (9 ± 0.5 mg/dl) with apoC-III. These observations were consistent 
with the previously reported values (4, 7). Among the novel HDL subspecies, the most abundant 
one was apoC-I-containing HDL, with 14% of apoA-I in association with apoC-I (20 ± 5 mg/dl). 
HDL subspecies containing apoJ, A1AT, plasminogen and apoC-II comprised 7% (10 ± 0.5 
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mg/dl), 5% (7 ± 0.7 mg/dl), 3% (4 ± 0.2 mg/dl) and 1% (1.5 ± 0.3 mg/dl) of the total apoA-I in 
HDL, respectively.  
 
ApoB lipoproteins with apoC-III 
We found that 7% of apoB (6 ± 0.8 mg/dl) was associated with apoC-III (Figure 1-5B), 
which also agrees with our previous finding using immunoaffinity chromatography (26).  
 
DISCUSSION 
To examine whether proteins identified to be located in HDL size or density range by 
proteomics studies also constitute apoA-I HDL subspecies, we developed a novel sandwich 
ELISA that can measure the concentrations of apoA-I HDL subspecies with or without a protein 
of interest. We confirmed that the three known HDL subspecies containing apoA-II, apoC-III 
and apoE comprised 70%, 6% and 10% of total apoA-I HDL, respectively. In addition, we 
identified and quantified five new HDL subspecies containing apoC-I, apoJ, A1AT, plasminogen 
and apoC-II that comprised 14%, 7%, 5%, 3% and 1% of apoA-I HDL, respectively. This 
finding is important because some of the novel HDL subspecies might also differ in their 
association with diseases such as CHD and diabetes and therefore serve as valuable predictors. 
We also showed that our modified sandwich ELISA is also applicable to apoB lipoprotein 
subspecies.  
The eight proteins investigated have unique properties that may confer specific 
functions to HDL. HDL proteomics studies have compared protein profiles of CAD patients with 
those of healthy people and found that some proteins were enriched in HDL of patients with 
CAD (14, 17, 25). The findings from these studies, however, were not consistent with regard to 
14 
 
 
which HDL proteins were enriched in CAD patients. Moreover, these studies were limited 
because of the small sample size and the cross-sectional design. In two large prospective cohort 
studies, the Nurses Health study and Health Professional Follow-up study, we found that HDL 
that does not contain apoC-III was associated with decreased CHD risk but HDL that contains 
apoC-III was associated with increased CHD risk (9). HDL seems to provide a platform or act as 
a vehicle for such proteins to exert their effect. In mice, treatment with A1AT-enriched HDL 
resulted in greater protection against elastase-induced pulmonary emphysema than treatment 
with HDL or A1AT alone, demonstrating that vectorization of A1AT by HDL provides some 
sort of directionality towards sites containing free elastase and represents a better means of 
delivering A1AT (27). Furthermore, supplementation of HDL with purified clusterin (apoJ) 
increased its endothelial anti-apoptotic effects, whereas clusterin alone did not have such effects 
(25). Some of the proteins may also influence kinetics of HDL. For example, apoA-II-containing 
apoA-I HDL have a slower turnover rate than non-apoA-II-containing apoA-I HDL in 
normolipidemic people (6), which was reversed in patients with LCAT deficiency (5). In 
abetalipoproteinemia, apoE containing HDL is cleared more rapidly from the circulation than 
HDL that does not have apoE (28). 
Immunoaffinity chromatography has played an important role thus far for the speciation 
of lipoproteins such as apoE-containing apoB lipoproteins and apoC-III-containing apoA-I 
lipoproteins. This method, however, has a number of disadvantages; the assay is time-consuming 
and costly, and has fairly high inter- and intra-assay CV%. We demonstrated in this paper that our 
modified sandwich ELISA could attenuate these disadvantages. First, the novel ELISA is faster 
because the entire protocol is completed in one day after overnight incubation of plasma samples, 
while the immunoaffinity chromatography method requires an additional day. Second, the 
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modified sandwich ELISA can process a larger number of samples per assay because of simpler 
procedures. Unlike immunoaffinity chromatography, the modified sandwich ELISA does not 
require elution of bound lipoproteins from a column and concentration of samples. Third, it is 
substantially cheaper because this method requires much less antibody. Finally, we confirmed the 
validity of the modified sandwich ELISA against immunoaffinity chromatography and showed 
that our modified sandwich ELISA has improved reproducibility both within an assay and between 
assays. The advantages of the modified sandwich ELISA make studies of the associations between 
HDL subspecies and disease feasible, and allow risk prediction in large population studies.  
Previous efforts have sought to establish a convenient ELISA that measure lipoprotein 
subspecies. Fruchart and colleagues developed a sandwich ELISA, where they capture apoC-III, 
for example, by a coating antibody, add apoB detection antibody conjugated to peroxidase, and 
develop by OPD, without delipidating the lipoprotein particle (29). This seemingly simple assay, 
however, has not been used subsequently to our knowledge. We tried to apply their ELISA to 
measure apoA-I with and without apoC-III but this method did not work for our purpose because 
it produced only weak signals. One possible explanation is that the epitopes of the apoA-I protein 
may be hidden by apoC-III, which exists in association with the HDL particle far more 
abundantly than apoA-I. We found that an average of four apoC-III molecules per apoA-I 
molecule are present in the HDL subspecies that has apoC-III (7). Because most HDL have four 
molecules of apoA-I (8), approximately 16 molecules of apoC-III could reside on apoC-III 
containing HDL.  
Our modified sandwich ELISA method has limitations, however. It cannot measure the 
concentration of HDL associated with multiple proteins simultaneously, while it is likely that 
some HDL particles contain more than one protein in addition to apoA-I. High throughput 
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methods such as mass spectrometry allow identification of many proteins in HDL all at once. 
However, mass spectrometry can only measure the concentrations of HDL proteins themselves, 
which may not be informative in the CVD risk prediction based on our previous finding that it 
was the concentration of apoA-I associated with apoC-III that predicted CVD risk, more so than 
the concentration of apoC-III contained in HDL (9). Another limitation is that the modified 
sandwich ELISA requires three ELISA plates in total, but it provides three independent 
measurements: plasma total apoC-III, apoA-I in HDL with apoC-III, and apoA-I in HDL without 
apoC-III.  
In conclusion, we established a novel sandwich ELISA, which confirmed the existence 
of eight apoA-I HDL subspecies investigated and showed that they exist in abundance with 
potential biological importance. The method is suitable for studying HDL and apoB lipoprotein 
subspecies in relation to dyslipidemia, CVD risk and treatments in large population studies. Our 
novel ELISA method may also enable a diagnostic test with an improved CVD risk predictability 
in the future.  
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Table 1-1. Eight proteins selected for discovery and characterization of apoA-I HDL 
subspecies 
Tables 
  
Reference 
plasma levels 
(mg/dl) 
Molecular 
weight 
(KDa) 
Functions 
ApoA-II 45 17 
The second major HDL apolipoprotein. Lipid 
metabolism and transport 
ApoC-I 11 6.6 
An LCAT activator and CETP inhibitor when 
associated with HDL. Inhibitor of LPL and 
hinders apoE mediated uptake of lipoproteins by 
the liver 
ApoC-II 7 8.8 Activates LPL  
ApoC-III 14 8.8 
Hinders apoE mediated uptake of lipoproteins by 
the liver. Both LDL and HDL associated with 
apoC-III predict increased CVD risk 
ApoE 9 34 Mediates uptake of lipoproteins by the liver 
ApoJ 5 70 
A complement inhibitor. Lipid transport. 
Apoptosis inhibitor 
Plasminogen 13 83 
Precursor of plasmin, which lyses fibrin clots to 
fibrin degradation products, Resolves clotting 
Alpha1-antitrypsin 175 52 Serine proteinases inhibitor, Stabilizes plaque 
 
20 
 
 
Table 1- 2. Characteristics of four plasma pools of healthy participants 
 
 Pool 1 Pool 2 Pool 3 Pool 4 
  
(high TG / low 
HDL chol) 
(high LDL 
chol) 
(high total 
apoA-I) 
(low TG / low 
LDL chol) 
Age, median (range) 32 (27-57) 44 (29-57) 30 (27-64) 29 (23-35) 
Gender         
     Male 2 2 0 3 
     Female 3 2 5 6 
Total Cholesterol (mg/dl) 178 224 174 157 
LDL Cholesterol (mg/dl) 113 157 102 95 
HDL Cholesterol (mg/dl) 36 45 45 49 
TG (mg/dl) 139 116 116 67 
Total apoA-I (mg/dl) 123 147 174 142 
ApoA-I without apoC-III 
(mg/dl) 
116 138 163 134 
ApoA-I with apoC-III 
(mg/dl) 
7.0 9.2 11.4 8.0 
Total apoB (mg/dl) 92 82 68 59 
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Table 1-3. Intra-assay and inter-assay reproducibility 
 
 Intra-assay CV% 
 
Inter-assay CV% 
  ApoC-III 
ApoA-I 
without 
apoC-III 
ApoA-I 
with  
apoC-III 
 
ApoC-III 
ApoA-I 
without 
apoC-III 
ApoA-I 
with  
apoC-III 
Immunoaffinity 
Chromatography 
6.6 7.1 11.6 
 
29.3 15.7 19.9 
ELISA 4.7 5.2 8.4 
 
8.6 13.6 8.2 
 
Values are shown as the mean of the four pools.  
Inter-assay CV% was calculated from three independent assays.  
Intra-assay CV% was calculated from triplicates within each assay and the means of three assays are shown.  
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Supplementary Table 1-1. Antibodies and optimal conditions for the modified sandwich 
ELISA  
 
 Protein 
Coating  
Antibody 
Detection 
Antibody for the 
first plate a 
Detection 
Antibody for the 
second plate b 
Detection 
Antibody for 
the third plate c 
ApoA-I 
HDL 
proteins 
ApoA-II 
Goat Anti-Human 
ApoA-II, 
Academy 
Biomedical  
(#12A-G1b,  
5 μg/ml) 
HRP-Goat Anti-
Human ApoA-II, 
Academy 
Biomedical  
(#12H-G2b, 1 
μg/ml) 
HRP-Goat Anti-
Human ApoA-I, 
Academy 
Biomedical  
(#11H-G1b, 1 
μg/ml) 
Biotin-Goat 
Anti-Human 
ApoA-I, 
Academy 
Biomedical  
(#11B-G2b, 1 
μg/ml) 
ApoC-I 
Rabbit Anti-Human 
ApoC-I, 
Academy 
Biomedical  
(#31A-R1b,  
5 μg/ml) 
HRP-Goat Anti-
Human ApoC-I, 
Academy 
Biomedical  
(#31H-G1b, 1 
μg/ml) 
ApoC-II 
Rabbit Anti-Human 
ApoC-II, 
Academy 
Biomedical  
(#32A-R1b,  
10 μg/ml) 
HRP-Goat Anti-
Human ApoC-II, 
Academy 
Biomedical  
(#32H-G4b, 1 
μg/ml) 
ApoC-III 
Rabbit Anti-Human 
ApoC-III, 
Academy 
Biomedical  
(#33A-R1b,  
10 μg/ml) 
HRP-Goat Anti-
Human ApoC-III, 
Academy 
Biomedical  
(#33H-G2b, 1 
μg/ml) 
ApoE 
Goat Anti-Human 
ApoE, 
Academy 
Biomedical 
(#50H-G1b,  
10 μg/ml) 
HRP-Goat Anti-
Human ApoE, 
Academy 
Biomedical 
(#50S-G1b, 1 
μg/ml) 
ApoJ 
Goat Anti-Human 
ApoJ,  
Millipore  
(#AB825, 5 μg/ml) 
Goat Anti-Human 
ApoJ, 
Millipore  
(#AB825d, 1 μg/ml) 
A1AT 
Rabbit Anti-Human 
A1AT, 
NOVUS  
(#NBP1-78098,  
5 μg/ml) 
Rabbit Anti-Human 
A1AT, 
NOVUS  
(#NBP1-78098d, 1 
μg/ml) 
Plasminogen 
Goat Anti-Human 
Plasminogen, 
Academy 
Biomedical  
(#PG60A-G1b,  
10 μg/ml) 
HRP-Goat Anti-
Human 
Plasminogen, 
Academy 
Biomedical  
(#PG60H-G1a, 1 
μg/ml) 
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ApoB 
protein 
ApoC-III 
Rabbit Anti-Human 
ApoC-III, 
Academy 
Biomedical  
(#33A-R1b, 10 
μg/ml) 
HRP-Goat Anti-
Human ApoC-III, 
Academy 
Biomedical  
(#33H-G2b, 1 
μg/ml) 
HRP-Goat Anti-
Human ApoB-
100/48, 
Academy 
Biomedical  
(#20H-G1b, 1 
μg/ml) 
Biotin-Goat 
Anti-Human 
ApoB-100/48, 
Academy 
Biomedical  
(#20B-G1b, 1 
μg/ml) 
 
a: Plate that measures the concentration of the protein of interest 
b: Plate that measures the concentration of apoA-I or apoB that is not associated with the protein of interest  
c: Plate that measures the concentration of apoA-I or apoB that is associated with the protein of interest  
d: HRP was conjugated to the same antibody as the coating antibody (EZ-link Plus Activated Peroxidase, 
Thermo SCIENTIFIC, #31489). 
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Figure 1-1. The novel sandwich ELISA procedure, using apoA-I with and without apoC-III 
as an example 
Figures 
 
 
  
25 
 
 
Figure 1-2. Absorbance values of a serially diluted plasma sample 
 
    
 
 
 
Data are the mean of 2 separate assays (each measured in triplicate) with bars indicating ± se. The highest 
concentration corresponds to 1:10,000 dilution and the sample was diluted serially 2x up to 1:640,000. 
The absorbance decreased dose-dependently as the dilutions increased for (a) total apoC-III, (b) apoA-I 
without apoC-III and (c) apoA-I with apoC-III.   
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Figure 1-3. Comparison of unaltered plasma samples to those same samples depleted of 
apoC-III-containing lipoproteins 
 
 
      
 
 
Plasma samples with low (Participant 1), medium (Participant 2) and high (Participant 3) levels of apoA-I 
with apoC-III were used. Data are the mean of 2 separate assays (each measured in triplicate) with bars 
indicating ± se. (a) Plasma apoC-III was detected only in unaltered samples. (b) ApoA-I without apoC-III 
was detected both in unaltered and altered samples. (c) ApoA-I with apoC-III was detected only in 
unaltered samples. 
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Figure 1-4. Comparison of the values for the four plasma pools (Pools 1-4) obtained from 
the modified sandwich ELISA with reference levels determined by immunoaffinity 
chromatography 
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Data are the mean of five separate assays (each measured in triplicate) with bars indicating ± sd. (a) The 
correlations between the two methods were 0.96, 0.91 and 0.89 for apoC-III, apoA-I without apoC-III and 
apoA-I with apoC-III, respectively. (b) The mean absolute deviations of the ELISA values from 
immunoaffinity chromatography were 25%, 9% and 15% for apoC-III, apoA-I without apoC-III and 
apoA-I with apoC-III, respectively.  
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Figure 1-5. The concentrations of apoA-I associated with HDL proteins (a) and the 
concentration of apoB associated with apoC-III (b) 
 
 
 
Each data point is the average of the four pools. On the right is the percentage of apoA-I or apoB 
associated with each HDL protein, calculated as 
ApoA−I with HDL protein
Total apoA−I
 or 
ApoB with apoC−III
Total apoB
.   
(A) 
(B) 
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Apolipoprotein C-III diminishes the beneficial association between HDL 
and insulin sensitivity: a multi-center cohort study 
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ABSTRACT 
 
Background 
Recent findings suggest that HDL directly exerts beneficial effects on the regulation of glucose 
metabolism. Previously we found that a subspecies of plasma HDL, comprising 6-7% of HDL-
apoA-I, has apolipoprotein C-III (apoC-III), a protein known for its proinflammatory properties. 
We hypothesized that the antidiabetic properties of HDL are attributed only to HDL that does not 
have apoC-III and that if apoC-III is present on HDL, apoC-III would diminish the beneficial 
effects of HDL on insulin synthesis and secretion.  
 
Methods 
We investigated the associations between the apoA-I concentrations of HDL subspecies with and 
without apoC-III and insulin sensitivity over 3 years among 864 participants from the European 
multi-center “Relationship between Insulin Sensitivity and Cardiovascular disease” (RISC) study.  
The concentrations of apoC-III-based HDL subspecies were measured at baseline (2002) by a 
sandwich ELISA. Insulin sensitivity was measured by oral glucose tolerance test (OGTT) at 
baseline and year 3.  
 
Findings 
ApoA-I in HDL with and without apoC-III demonstrated significantly opposite associations with 
3-year change in insulin sensitivity (p-heterogeneity=0.004). The highest quintile of apoA-I in 
HDL with apoC-III was associated with a 1.2% reduction in insulin sensitivity (p-trend=0.02), 
while the highest quintile of apoA-I without apoC-III was associated with a 1.3% improvement 
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(p-trend=0.01), compared to the lowest quintile. Total apoA-I was not associated with 3-year 
change in insulin sensitivity (p=0.3). The concentration of apoC-III contained in HDL was 
associated with a decrease in insulin sensitivity (-1.3% per 1 SD higher level; p=0.002) even 
more strongly than plasma total apoC-III (-0.6% per 1 SD higher level; p=0.11).  
 
Interpretation 
Both the concentration of an HDL subspecies that has apoC-III and the concentration of apoC-III 
itself in HDL appeared to adversely affect the beneficial properties of HDL on the insulin 
response to glucose. Our results support the potential of HDL apoC-III as a promising target for 
diabetes prevention and treatment. 
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INTRODUCTION  
HDL is a heterogeneous group of lipoprotein particles. We recently found that HDL 
exists in subspecies based on the presence of apolipoprotein (apo) C-III, a small protein known 
for its proinflammatory properties. In healthy adults, apoC-III is present on about 6-7% of HDL, 
as measured by the plasma total apoA-I, the main HDL apolipoprotein (1), whereas the 
remaining HDL is free of apoC-III. The classification of HDL into subspecies based on the 
presence or absence of apoC-III may have important implications for disease risk, as apoC-III-
based HDL subspecies differ in their metabolic properties and downstream biologic interactions; 
HDL that contains apoC-III has been associated with a higher prevalence of obesity and an 
elevated risk of coronary heart disease, opposite to what has been seen for total HDL or HDL 
that does not contain apoC-III (1, 2).  
Recent evidence suggests that apoC-III-based HDL subspecies might similarly relate to the 
development of insulin resistance and diabetes. Several studies have suggested that HDL and 
apoA-I exert direct beneficial effects on the regulation of glucose metabolism through multiple 
mechanisms (3-5). However, we speculate that these antidiabetic effects of HDL are attributed 
only to HDL without apoC-III, and if apoC-III is present on HDL, apoC-III would diminish the 
beneficial effect of HDL on glycemic control. In cross-sectional analyses in the Nurses’ Health 
Study and Health Professionals Follow-Up Study, prevalent diabetes was associated with higher 
levels of HDL with apoC-III and lower levels of HDL without apoC-III (2).   
Indeed, apoC-III has a role in the pathogenesis of insulin resistance and diabetes. Transgenic 
mice with human apoC-III overexpression have been shown to develop hepatic triglycerides 
accumulation and diet-induced insulin resistance (6). Mechanistic studies in cells and animal 
models have demonstrated that apoC-III increases cytokine expression in cultured monocytes 
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and endothelial cells (7-9) and pancreatic β-cell apoptosis via hyperactivation of β-cell CaV 
channels (10, 11). These mechanisms link apoC-III to inflammation, pancreatic β-cell function 
and insulin resistance. Elevated plasma apoC-III concentration is a feature of dyslipidemia in 
obesity and observed in both type 1 and 2 diabetes (11-13). Several cross-sectional studies (14-
16) and one prospective cohort study (17) showed that high levels of apoC-III were associated 
with diabetes or metabolic syndrome. Further, a group of New York Ashkenazi Jews having 
genetically reduced plasma apoC-III concentration maintained greater insulin sensitivity with age 
and reached exceptional longevity (18).  
Therefore, we hypothesized that only HDL without apoC-III would be beneficially associated 
with insulin sensitivity, whereas HDL with apoC-III would be associated with impaired insulin 
sensitivity. We also studied the concentration of total apoC-III as well as the concentration of 
apoC-III itself that is contained in HDL. In addition, we examined apoB-containing lipoproteins, 
VLDL and LDL, with and without apoC-III.   
 
 
MATERIALS AND METHODS 
Study design and participants 
RISC is a European multi-center, prospective cohort study with a standardized protocol 
and a centralized evaluation of measures (19). Healthy men and women ages 30-60 (n=1,513) 
were recruited between June 2002 and July 2004 from the local population at 19 centers in 14 
European countries (Austria, Denmark, Finland, France, Germany, Greece, The Netherlands, 
Ireland, Italy, Sweden, Spain, Switzerland, United Kingdom and Serbia and Montenegro). 
Follow-up examinations were performed after 3 years. Exclusion criteria were treatment for any 
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chronic disease, pregnancy, any cardiovascular event, weight change of ≥5 kg in the last 3 
months, cancer in the last 5 years, and renal or liver failure, recent major surgery, seizure 
disorder or epilepsy, arterial blood pressure ≥140/90 mmHg, fasting plasma glucose ≥7.0 
mmol/L (126 mg/dl), 2-hour plasma glucose (on a standard 75-g OGTT) ≥11.0 mmol/L (200 
mg/dl), total serum cholesterol ≥7.8 mmol/L (300 mg/dl), serum triglycerides ≥4.6 mmol/L (400 
mg/dl), electrocardiogram abnormalities or acute myocardial ischemia injury or pericarditis. Out 
of 1,017 eligible subjects whose apolipoprotein levels were initially measured by the RISC 
investigators, baseline plasma samples of 987 subjects, which had enough plasma left for our 
experiment, were sent to our laboratory.  Each recruiting center obtained approval from local 
ethics committee. 
 
Exposure assessment 
Information on basic characteristics of the participants including demographics (age, sex) 
and lifestyle (smoking, alcohol consumption, physical activity based on the International 
Physical Activity Questionnaire (IPAQ) score) were collected by interviews and questionnaires. 
Anthropometric measures and lipid levels (LDL-, HDL-, total-cholesterol and triglycerides) were 
also measured (19). 
We used a novel sandwich ELISA that we recently developed to measure the 
concentrations of total apoC-III, apoA-I in HDL without apoC-III, apoA-I in HDL with apoC-III; 
and the concentrations of apoB in lipoproteins with and without apoC-III (Yamamoto et al 2015, 
submitting). Briefly, a 96-well microplate coated with anti-human apoC-III antibody captured 
plasma lipoproteins that contained apoC-III. The unbound fraction was transferred to another 
plate coated with anti-human apoA-I antibody to measure the concentration of apoA-I that was 
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not associated with apoC-III. The lipoproteins bound to the anti-apoC-III plate were dissociated 
with Tween-20, and then transferred to a plate coated with anti-human apoA-I antibody to 
measure the concentration of apoA-I that contained apoC-III. Total apoA-I was calculated as the 
sum of the concentrations of apoA-I with and without apoC-III.  The concentrations of apoB 
with and without apoC-III were measured by applying the same principle for the apoA-I 
subspecies.  
For the measurement of the apoC-III concentration in HDL, whole plasma was 
precipitated with dextran sulfate and magnesium chloride to remove apoB-containing 
lipoproteins, and the apoC-III concentration in the remaining fraction was measured by standard 
sandwich ELISA. The apoC-III concentration in HDL is different from the apoA-I concentration 
of HDL with apoC-III; the former represents the concentration of apoC-III itself contained in 
HDL whereas the latter represents the concentration of apoA-I in HDL with any amount of 
apoC-III. The apoC-III to apoA-I molar ratio, which may be interpreted as the density of apoC-
III on apoC-III-containing HDL, was calculated as the number of apoC-III molecules per apoA-I 
molecule on HDL particles containing apoC-III.  To correct apolipoprotein measurements for 
moderate variability by batch, values of each apolipoprotein exposure were recalibrated to 
represent the average distribution across batches using methods developed by Rosner et al (20). 
To perform the recalibration, we used a linear model regressing apolipoprotein levels on batch as 
well as age, sex, center, alcohol, smoking, physical activity, and BMI, variables associated with 
apolipoprotein levels in our study population. 
 
Outcome assessment 
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A standard 75g-OGTT was performed in the morning after an overnight fast at baseline 
and at 3-year follow-up in this study. Blood samples were taken at 0, 30, 60, 90, and 120 min 
after glucose ingestion. The plasma concentrations of glucose and insulin were measured for 
each time point. OGIS is an insulin sensitivity index calculated from OGTT measurements and is 
a validated estimate of the glucose clearance during a euglycemic-hyperinsulinemic clamp (21). 
The calculation is based on an equation derived from a regression model of the glucose-insulin 
relationship. In this paper, OGIS will be referred to as insulin sensitivity measured by OGTT (IS-
OGTT). 
On a separate day within one month of the baseline OGTT, a euglycemic-
hyperinsulinemic clamp was performed. The clamp test was not repeated at 3 years. Insulin was 
administered as a primed-continuous infusion at a rate of 240 pmol/min/m2 simultaneously with 
a variable 20% dextrose infusion adjusted every 5–10 min to maintain plasma glucose level 
within 0.8 mmol/L (±15%) of the target glucose level (4.5–5.5 mmol/L). Additional blood 
samples were obtained at 20-min intervals for insulin determination. The clamp procedure was 
standardized across centers. The M-I ratio is an insulin sensitivity index obtained from the 
clamp, which represents the amount of glucose metabolized per unit of plasma insulin. In this 
paper, the M-I ratio will be referred to as insulin sensitivity measured by clamp (IS-clamp). 
 
Statistical analysis  
Baseline characteristics of participants were described in men and women separately 
using medians for continuous variables and percentages for categorical variables.  
The top and bottom 1% of the apolipoprotein exposures were trimmed to minimize the 
influence of outliers (n=20 removed). Observations that were missing any outcome 
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measurements (baseline or year 3 IS-OGIS or baseline IS-clamp) were deleted (n=97 removed).  
We used the extreme studentized deviate (ESD) procedure to identify and exclude outliers (n=3 
removed) (22, 23) and excluded observations with residuals larger than 4 standard deviations 
(SDs) (n=3 removed). The final sample size was 864. 
Linear regressions were performed to evaluate the relationships between apolipoprotein 
variables and outcomes. All outcome variables were log-transformed to improve normality. Sex-
specific quintiles and quintile medians were created for each apolipoprotein variable, as baseline 
apolipoprotein levels were different between men and women. Tests for trend were based on 
quintile medians. Nonlinearity was assessed with likelihood-ratio tests, comparing a model 
treating quintile medians continuously to a model with quintile indicators. After confirming there 
were no deviations from linearity (all p for nonlinearity > 0.05), we also created sex-specific z-
scores to analyze associations per SD. We back-transformed the coefficients to present results as 
the percent (%) difference in insulin sensitivity outcome per each SD higher or for each quintile 
compared with the lowest quintile. Potential confounders were selected based on our a priori 
knowledge as to the associations with the apolipoproteins as well as their effect on insulin 
sensitivity. Multivariable models were adjusted for age, sex, center, smoking (never smoked; 
previously smoked; currently smokes 1 to 14.9, ≥15 tobacco grams per day), alcohol 
consumption (women: 0, 0.1 to 4.9, 5.0 to 14.9, or ≥15.0 g per day; men: 0, 0.1 to 4.9, 5.0 to 
29.9, or ≥30.0 g per day), physical activity (inactive; minimally active; highly active; or not 
reported) and BMI (continuous). For the main prospective analysis with IS-OGTT at year 3 as 
the outcome, log-transformed IS-OGTT at baseline was additionally adjusted as a covariate in 
the model. In this way, the model analyzes the 3-year change in IS-OGTT. Because apoA-I with 
and without apoC-III represent fractions of total apoA-I, the two apoA-I subspecies were entered 
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in the model simultaneously. Likewise, both apoB with and without apoC-III were included in 
the models for apoB subspecies. Likelihood ratio tests were performed based on linear trends to 
assess whether associations varied significantly for apoC-III-based lipoprotein subspecies. We 
ran additional regression models with the % of apoA-I with apoC-III simultaneously adjusting 
for the total concentration of apoA-I in the model. A model for apoC-III in HDL was also 
adjusted for total apoA-I. Multivariable models were additionally adjusted for triglycerides, 
which was considered a potential intermediate between apoC-III and insulin response.  To 
investigate whether the associations we observed between apoA-I related measurements and 
insulin sensitivity are modified by risk factors for insulin resistance or diabetes, we tested for 
effect modification by sex, BMI (<20, 20-25, ≥25 kg/m²), triglycerides (<150, ≥150 mg/dl) and 
HDL-cholesterol (<40, 40-60, ≥60 mg/dl) using likelihood ratio tests.  
 
RESULTS 
Study participant characteristics 
The median age of study participants was 43 for men and 45 for women, and the median 
BMI was 26 kg/m2 for men and 24 kg/m2 for women. In general, participants had healthy lipid 
profiles, with high HDL cholesterol (median for men: 1.2 mmol/l, women: 1.5 mmol/l) and low 
LDL cholesterol (median for men: 3.0 mmol/l, women: 2.8 mmol/l) and triglycerides (median for 
men: 1.1 mmol/l, women: 0.8 mmol/l) (Table 1). During the 3-year follow-up, only 3 
participants developed diabetes.  
 
Associations between apolipoprotein concentrations and 3-year change in insulin sensitivity     
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ApoA-I in HDL with and without apoC-III measured at baseline demonstrated 
significantly opposite associations with 3-year change in IS-OGTT (p-heterogeneity=0.004) 
(Figure 2-1A, Table 2-2). Each 1 SD higher apoA-I without apoC-III (19 mg/dL for men and 22 
mg/dL for women) at baseline was associated with a 1.3% improvement in IS-OGTT after 3 
years (95% CI: 0.3, 2.2), while each 1 SD higher apoA-I with apoC-III (2.5 mg/dL for men and 
2.7 mg/dL for women) was associated with a 1.2% decrease in IS-OGTT (95% CI: -2.1, -0.3). 
This was corroborated by the result from a model using the % of apoA-I with apoC-III as a main 
exposure, which was significantly associated with a decrease in IS-OGTT over 3 years (Figure 2-
1B, Table 2-2). Total apoA-I was not significantly associated with a 3-year change in IS-OGTT. 
ApoC-III concentration in HDL was strongly associated with a decrease in IS-OGTT 
over 3 years. For every SD higher apoC-III in HDL (2.5 mg/dL for men and 2.0 mg/dL for 
women), IS-OGTT decreased by 1.3% (95%CI: -2.1, -0.5) (Figure 2-1C, Table 2-2). The similar 
inverse associations were present but weaker for total apoC-III and the molar ratio of apoC-III to 
apoA-I.  
None of the apoB measures (total apoB, apoB without apoC-III and apoB with apoC-III) 
were significantly associated with IS-OGTT assessed at year 3 (Supplementary Table 2-1). 
ApoC-III contained in apoB lipoproteins was weakly associated with a decrease in IS-OGTT; for 
every SD higher apoC-III in apoB lipoproteins, IS-OGTT decreased by 0.7% (95%CI: -1.5, 0.1).  
 
Adjusting for triglycerides 
All the significant associations between apolipoprotein levels and 3-year change in 
insulin sensitivity were attenuated and became null after triglycerides adjustment demonstrating 
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an apoC-III- triglycerides-insulin sensitivity pathway, as hypothesized (Supplementary Table 2-
2).  
 
Investigation of potential effect-modifiers  
We found no evidence of effect modification by sex, BMI, triglycerides or HDL-
cholesterol (P for interaction all >0.1).  
 
Cross-sectional results for IS-clamp and IS-OGTT  
We confirmed that total apoC-III, apoC-III in HDL and the apoC-III to apoA-I molar 
ratio were all significantly and inversely associated with both euglycemic-hyperinsulinemic 
clamp (IS-clamp) and IS-OGTT which were both available at the baseline exam. The order of 
strength of associations were similar for both endpoints (Figure 2-2A and B, Table 2-3). The 
apoC-III to apoA-I molar ratio had the strongest inverse association with both IS-clamp and IS-
OGTT, followed by apoC-III in HDL. A weaker but still significantly inverse association was 
present between total apoC-III and both insulin sensitivity indexes.  
 
DISCUSSION 
The present study is the first to show that two HDL subspecies, HDL with and without 
apoC-III, have significantly opposite associations with changes in insulin sensitivity. We found 
that apoA-I without apoC-III was associated with improved insulin sensitivity, whereas apoA-I 
with apoC-III was associated with worsened insulin sensitivity over 3 years. These findings 
pertaining to apoC-III-containing HDL are strengthened by our findings on the apoC-III 
concentration in HDL, which was strongly associated with a reduction in insulin sensitivity. 
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Measuring the HDL subspecies or apoC-III in HDL is necessary to reveal these associations that 
involve apoC-III because plasma total apoA-I was unassociated and total apoC-III was only 
weakly associated with insulin sensitivity. This is because the apoB subspecies and apoC-III in 
apoB lipoproteins have a null and very weak association with insulin sensitivity and dilute the 
significant associations between apoC-III related HDL measurements and insulin sensitivity.  
This and previous research indicate that the concept of HDL subspecies based on the 
presence or absence of apoC-III may have important implications for the risk of chronic diseases 
or metabolic conditions. The percentage of apoA-I in HDL that contains apoC-III in people with 
obesity was about 13-14%, which is double that of normal weight individuals (1). HDL with and 
without apoC-III demonstrated opposite associations with CHD risk in two prospective cohorts; 
HDL without apoC-III was associated with a decreased risk of CHD, whereas HDL with apoC-
III was associated with an increased risk (2). In a cross-sectional analysis within the same study, 
higher concentrations of hemoglobin A1c (HbA1c) and prevalent diabetes were associated with 
higher levels of HDL with apoC-III and lower levels of HDL without apoC-III. Although 
measuring the concentration of the HDL subspecies is more complex than the apoC-III 
concentration in HDL, there is more information in the subspecies concerning age-related 
changes in insulin sensitivity because they show beneficial and harmful associations.  
HDL and apoA-I are directly involved in glucose homeostasis (3-5), possibly by 
improving insulin secretion via reducing cholesterol accumulation in pancreatic β-cells (24, 25), 
increasing glucose uptake into skeletal muscle through the AMP-activated protein kinase 
signaling pathway (26, 27), improving insulin sensitivity via anti-inflammatory actions (28-30), 
and increasing insulin synthesis and secretion in pancreatic β-cells through incretin-like 
mechanisms (31). The present study demonstrated that the beneficial effects on insulin response 
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to glucose existed only for HDL without apoC-III, but not for HDL with apoC-III. Interestingly, 
total apoA-I levels were not associated with improvement in insulin sensitivity over 3 years, 
suggesting that the differential associations seen for HDL subspecies with and without apoC-III 
may be obscured by assessing only total apoA-I. There are potential mechanisms through which 
HDL with apoC-III might impair an otherwise favorable association of apoA-I in HDL with 
insulin sensitivity. HDL without apoC-III significantly inhibited human monocyte cell adhesion 
to cultured endothelial cells, in vitro, while HDL with apoC-III did not reduce adhesion (8), 
which suggests that the presence of apoC-III on HDL diminishes the anti-inflammatory effect of 
HDL without apoC-III. ApoC-III also promotes β-cell apoptosis by hyperactivation of β-cell 
CaV channels in vitro (11) and in vivo (10) and thus enhances insulin resistance. 
In a previous analysis in RISC, total apoC-III levels measured by multiplex were found to 
be inversely associated with insulin sensitivity measured as IS-clamp at baseline (32). We 
confirmed this cross-sectional finding, using ELISA, with both insulin sensitivity indexes 
measured by clamp and OGTT. This is consistent with several other epidemiological studies, 
which demonstrated that apoC-III is associated with diabetes or metabolic syndrome cross-
sectionally (14-16) and prospectively (17). Interestingly, we found that apoC-III in HDL was 
even more strongly and inversely associated with insulin sensitivity than total apoC-III levels in 
both cross-sectional and prospective analysis. This is consistent with a previous prospective 
cohort study on Turkish men and women, which has reported that apoC-III contained in HDL 
was associated with the risk of diabetes more strongly than total apoC-III (17). In another study, 
the concentration of apoC-III in HDL was significantly higher among obese people as compared 
to people with normal body weight (1). About 40% of apoC-III is in apoB lipoproteins which are 
very weakly associated with insulin sensitivity. 
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The results for apoB-lipoproteins were not significant. This might be because apoB-
containing lipoproteins in this study contained both LDL and VLDL instead of only LDL. 
Mendivil et al 2011 showed that apoB in LDL with apoC-III was associated with increased risk 
of CHD, whereas the association between apoB in LDL without apoC-III and CHD risk was null 
(33). The same study showed no differential effects by VLDL subspecies, with both apoB in 
VLDL with and without apoC-III being associated with increased risk of CHD. In contrast, Lee 
et al 2003 showed that VLDL with apoC-III was associated with decreased risk for recurrent 
coronary events among diabetic patients, while VLDL without apoC-III was associated with 
increased risk (34). Similar to the present data from RISC, our unpublished data from the Danish 
Diet, Cancer and Health study cancer cohort study demonstrated similarly that total apoB (in 
both LDL and VLDL) with apoC-III was not associated with the incidence of diabetes. These 
results suggest a need to look at LDL and VLDL separately when examining their apoC-III 
defined subspecies with the risk of diabetes or CHD.  
There are several strengths in our study. First, the RISC study is the largest study to date 
which used the gold standard technique, the euglycemic-hyperinsulinemic clamp, for measuring 
insulin sensitivity in healthy nondiabetic people. The euglycemic-hyperinsulinemic clamp was 
administered only at baseline, whereas OGTT was performed both at baseline and year 3. OGIS 
is a validated estimate of clamp-measured insulin sensitivity and we confirmed in this study that 
the two methods provided the same patterns of associations with apolipoprotein levels at baseline 
before we conducted the main prospective analysis using IS-OGTT at year 3. Second, the 
sandwich ELISA method has relatively low within-assay and between-assay variability 
compared to other methods such as immuno-affinity chromatography (Yamamoto et al 2015, 
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submitting). Finally, since all assays were performed by one analyst, there was no inter-rater 
variability.  
Our study also has a number of limitations. Although we were able to perform 
prospective analysis, 3 years might not have been long enough for insulin sensitivity to 
substantially change, especially because the participants of this cohort were quite healthy at 
baseline. Another limitation is the variation across study sites due to the multi-center design of 
the RISC study. However, the exposure measurement was performed independently of the 
outcome assessment and blinded to the outcome status. Therefore, it is likely that the variation 
was non-differential and the effect estimates were pulled toward the null. Finally, the 
generalizability of the study was limited since the participants were all Europeans. Future studies 
using cohorts with different ethnic compositions are needed for improved generalizability.  
In conclusion, in this prospective analysis of healthy men and women in the RISC cohort, 
two HDL subspecies had significantly opposite associations with 3-year change in insulin 
sensitivity, with HDL with apoC-III being associated with a decrease in insulin sensitivity and 
HDL without apoC-III associated with an increase in insulin sensitivity. In addition, the 
concentration of apoC-III contained in HDL had a strong and significant association with a 
decrease in insulin sensitivity over 3 years. Our results support the potential of HDL apoC-III as 
a promising target for diabetes prevention and treatment and have implications for a refined 
approach based on apoC-III content of future therapeutic targets for diabetes prevention. 
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Table 2-1. Baseline characteristics of men and women in the RISC study included in this 
study 
Tables 
  
Men Women 
Median 
25th, 75th  
percentile 
Median 
25th, 75th  
percentile 
Age, yrs 43 (36, 51) 45 (39, 51) 
BMI, kg/m2 26 (24, 28) 24 (22, 27) 
Systolic BP, mmHg 123 (116, 130) 114 (105, 123) 
Diastolic BP, mmHg 77 (71, 81) 73 (67, 78) 
Physical activity (IPAQ), % 
(inactive/moderate/active) 
20/42/39, % 20/44/37, % 
Alcohol, g/wk 76 (35, 143) 34 (11, 67) 
Smoker, % 
(never/current/ex) 
47/26/26, % 48/24/28, % 
Menopause, % - 26% 
Fasting glucose, mmol/l 5.2 (4.9, 5.5) 5.0 (4.7, 5.3) 
Fasting insulin, pmol/l 31 (22, 46) 30 (20, 41) 
IS-clamp  (baseline), 
µmol/min*kg_FFM*nM 
116 (83, 153) 149 (111, 192) 
IS-OGTT (baseline), 
ml/min*m2 
427 (392, 461) 447 (410, 488) 
IS-OGTT (year 3), ml/min*m2 414 (378, 451) 438 (393, 483) 
delta_IS-OGTT, ml/min*m2 -13 (-42, 18) -8 (-46, 24) 
Adiponectin, mg/l 6 (5, 8) 9 (7, 12) 
Leptin, ng/ml 5 (2, 8) 15 (10, 25) 
Cholesterol, mmol/l 4.9 (4.4, 5.5) 4.8 (4.2, 5.3) 
HDL-C, mmol/l 1.2 (1.1, 1.4) 1.5 (1.3, 1.8) 
LDL-C, mmol/l 3.0 (2.6, 3.6) 2.8 (2.3, 3.3) 
TG, mmol/l 1.1 (0.8, 1.5) 0.8 (0.6, 1.1) 
FFA, mmol/l 0.43 (0.35, 0.57) 0.56 (0.45, 0.72) 
ApoA-I without apoC-III, 
mg/dl 
90 (78, 103) 103 (89, 118) 
ApoA-I with apoC-III, mg/dl 7.4 (6.0, 8.9) 8.4 (7.0, 10.4) 
% of apoA-I with apoC-III, % 7.5 (6.4, 8.9) 7.6 (6.6, 8.8) 
ApoB without apoC-III, mg/dl 71 (61, 87) 67 (55, 80) 
ApoB with apoC-III, mg/dl 4.3 (3.3, 5.5) 4.0 (3.1, 5.1) 
% of apoB with apoC-III, % 5.6 (4.5, 6.9) 5.8 (4.6, 7.0) 
ApoC-III, mg/dl 9.9 (7.6, 12.8) 9.9 (7.6, 12.3) 
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ApoC-III in HDL, mg/dl 5.8 (4.6, 7.6) 5.7 (4.6, 7.0) 
ApoC-III in apoB, mg/dl 4.1 (2.8, 6.0) 4.2 (2.8, 5.6) 
ApoC-III : ApoA-I molar ratio 2.6 (2.2, 3.1) 2.2 (1.9, 2.6) 
ApoC-III : ApoB molar ratio 63 (43, 80) 62 (47, 84) 
 
BMI=body mass index, IPAQ=international physical activity questionnaire, BP=blood pressure, FFM=fat 
free mass, IS-clamp=insulin sensitivity measured by euglycemic-hyperinsulinemic clamp, IS-OGTT= 
insulin sensitivity measured by oral glucose tolerance test, HDL-C=HDL-Cholesterol, LDL-C=LDL-
Cholesterol, TG=triglycerides, FFA=free fatty acid, ApoA-I without apoC-III=the concentration of apoA-I 
in HDL that does not contain apoC-III, ApoA-I with apoC-III=the concentration of apoA-I in HDL that 
contains apoC-III, % of apoA-I with apoC-III=% of apoA-I in HDL that contains apoC-III, ApoB without 
apoC-III=the concentration of apoB in LDL and VLDL that does not contain apoC-III, ApoB with apoC-
III=the concentration of apoB in LDL and VLDL that contains apoC-III, % of apoB with apoC-III=% of 
apoB in LDL and VLDL that contains apoC-III, ApoC-III in HDL=the concentration of apoC-III contained 
in HDL fraction, ApoC-III in apoB=the concentration of apoC-III contained in LDL and VLDL, ApoC-III : 
ApoA-I molar ratio=the molar ratio of apoC-III to apoA-I in apoC-III-containing HDL, ApoC-III : ApoB 
molar ratio= the molar ratio of apoC-III to apoB in apoC-III-containing LDL and VLDL    
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Table 2-2. Association between apolipoprotein concentrations in HDL and 3-year change in insulin sensitivity 
 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI. Adjusted for log-transformed IS-
OGTT at baseline. Analysis of apoA-I without and with apoC-III simultaneously adjusted. Analysis of % apoA-I with apoC-III and apoC-III in 
HDL also adjusted for total apoA-I.   
Outcome Exposure 
Quintiles 
P-trend per SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
IS-OGTT 
(year 3) 
Total apoA-I 0% -0.5% 0.68 1.7% 0.14 2.3% 0.047 0.5% 0.65 0.25 0.4% 0.26 
ApoA-I without apoC-III 0% 1.3% 0.28 2.3% 0.051 4.6% 0.0004 2.8% 0.04 0.01 1.3% 0.01 
ApoA-I with apoC-III 0% -0.4% 0.73 -1.2% 0.30 -1.0% 0.42 -3.0% 0.03 0.02 -1.2% 0.01 
% apoA-I with apoC-III 0% -1.3% 0.24 -0.6% 0.57 -1.9% 0.09 -2.6% 0.02 0.02 -1.0% 0.005 
Total apoC-III 0% 1.1% 0.33 -0.5% 0.69 0.0% 0.97 -1.8% 0.11 0.049 -0.6% 0.11 
ApoC-III in HDL 0% -0.3% 0.77 -0.6% 0.63 -1.6% 0.18 -3.7% 0.004 0.002 -1.3% 0.002 
ApoC-III to apoA-I ratio 0% -0.8% 0.49 -1.2% 0.31 -1.6% 0.18 -2.1% 0.10 0.08 -0.8% 0.04 
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Table 2-3. Cross-sectional association between apolipoprotein concentrations in HDL and insulin sensitivity at baseline 
 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI.   
Outcome Exposure 
Quintiles 
P-trend per SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
IS-clamp 
Total apoC-III 0% 1.1% 0.80 -3.3% 0.42 -3.5% 0.40 -6.3% 0.12 0.04 -3.0% 0.02 
ApoC-III in HDL 0% -5.2% 0.19 -6.9% 0.09 -9.1% 0.03 -14.8% 0.0004 0.0003 -5.5% 0.0001 
ApoC-III to apoA-I ratio 0% -10.0% 0.01 -8.6% 0.03 -18.4% <0.0001 -22.3% <0.0001 <0.0001 -7.9% <0.0001 
IS-OGTT 
Total apoC-III 0% 1.0% 0.42 -0.6% 0.63 -0.4% 0.75 -1.6% 0.19 0.07 -0.8% 0.04 
ApoC-III in HDL 0% -0.3% 0.81 -0.6% 0.65 -1.5% 0.23 -3.2% 0.02 0.008 -1.5% 0.0008 
ApoC-III to apoA-I ratio 0% -2.6% 0.04 -3.3% 0.007 -4.8% 0.0001 -6.2% <0.0001 <0.0001 -2.1% <0.0001 
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Supplementary Table 2-1. Association between apolipoprotein concentrations in LDL and VLDL and 3-year change in insulin 
sensitivity 
 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI. Adjusted for log-transformed IS-
OGTT at baseline. Analysis of apoB without and with apoC-III simultaneously adjusted. Analysis of % apoB with apoC-III and apoC-III in apoB 
also adjusted for total apoB.  
Outcome Exposure 
Quintiles 
P-trend per SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
IS-OGTT 
(year 3) 
Total apoB 0% -2.4% 0.04 -0.5% 0.67 -1.1% 0.36 -2.1% 0.09 0.25 -0.5% 0.18 
ApoB without apoC-III 0% -1.7% 0.16 0.1% 0.96 -0.9% 0.50 -1.4% 0.32 0.52 -0.3% 0.53 
ApoB with apoC-III 0% 1.1% 0.36 1.2% 0.32 -0.9% 0.46 -0.2% 0.89 0.45 -0.4% 0.33 
% apoB with apoC-III 0% 0.0% 0.97 2.2% 0.06 -0.5% 0.69 -0.1% 0.94 0.78 -0.5% 0.22 
ApoC-III in apoB 0% -1.0% 0.41 -1.2% 0.32 -2.2% 0.08 -2.2% 0.08 0.048 -0.7% 0.09 
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Supplementary Table 2-2. Association between apolipoprotein concentrations in HDL and 3-year change in insulin sensitivity, 
additional TG adjustment 
 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity, BMI and TG. Adjusted for log-
transformed IS-OGTT at baseline. Analysis of apoA-I without and with apoC-III simultaneously adjusted. Analysis of % apoA-I with apoC-III and 
apoC-III in HDL also adjusted for total apoA-I. 
  
Outcome Exposure 
Quintiles  
P-trend 
 
per SD 
Q1 Q2 Q3 Q4 Q5   
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p  p  
% 
difference 
p 
IS-OGTT 
(year 3) 
Total apoA-I 0% -0.5% 0.64 1.5% 0.19 2.1% 0.07 0.6% 0.63  0.25  0.4% 0.24 
ApoA-I without apoC-III 0% 1.0% 0.40 1.8% 0.13 3.7% 0.004 1.9% 0.17  0.08  0.9% 0.07 
ApoA-I with apoC-III 0% 0.1% 0.96 0.6% 0.65 0.2% 0.87 1.6% 0.29  0.29  -0.6% 0.21 
% apoA-I with apoC-III 0% -1.1% 0.35 -0.3% 0.78 -1.5% 0.18 -1.2% 0.33  0.31  -0.6% 0.14 
Total apoC-III 0% 1.5% 0.21 0.3% 0.83 0.6% 0.62 0.2% 0.87  0.99  0.4% 0.43 
ApoC-III in HDL 0% -0.1% 0.96 0.0% 0.97 -1.0% 0.44 -1.9% 0.22  0.25  -0.6% 0.27 
ApoC-III to apoA-I ratio 0% -0.5% 0.70 -0.9% 0.43 -0.8% 0.54 -0.5% 0.72  0.80  -0.2% 0.65 
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Figure 2-1. Association between apolipoprotein concentrations in HDL and 3-year change in insulin sensitivity 
Figures 
 
     
   
Multivariable linear regression models adjusted for age, sex, 
center, alcohol, smoking, physical activity, BMI and log-
transformed IS-OGTT at baseline. Analysis of apoA-I without 
and with apoC-III simultaneously adjusted. Analysis of % 
apoA-I with apoC-III and apoC-III in HDL also adjusted for 
total apoA-I. 
P-heterogeneity in panel (A) comparing trends across quintiles 
of apoA-I with and without apoC-III. 
(A) (B) 
(C) 
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Figure 2-2. Cross-sectional association between apolipoprotein concentrations in HDL and insulin sensitivity at baseline 
 
 
     
 
  
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI.  
(A) (B) 
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ABSTRACT 
 
Background 
About 6-7% of High Density Lipoprotein (HDL) has apolipoprotein C-III (apoC-III), a 
protein known for its proinflammatory properties. When apoC-III is present on HDL, HDL 
loses its protective inverse association with risk of coronary heart disease (CHD), whereas 
HDL without apoC-III is strongly inversely associated with CHD. We investigated how the 
presence of apoC-III affects the association between HDL and early stages of atherosclerosis 
measured as carotid intima-media thickness (cIMT).    
 
Methods 
We examined the cross-sectional associations between the apoA-I concentrations of HDL 
subspecies with and without apoC-III and cIMT among 847 participants from the European 
multi-center “Relationship between Insulin Sensitivity and Cardiovascular disease” (RISC) study. 
The concentrations of these apoC-III-based HDL subspecies were measured by sandwich 
ELISA. cIMT at common carotid artery (cIMT at CCA) and the maximum cIMT (cIMT max) 
were measured by high resolution B-mode carotid ultrasonography. 
 
Findings 
HDL with and without apoC-III demonstrated significantly opposite associations with both 
cIMT indexes (p-heterogeneity of associations comparing the two subspecies was 0.002 for 
cIMT at CCA and 0.006 for cIMT max). Compared to the lowest quintile, the highest quintile 
of apoA-I without apoC-III was associated with 3.7% lower cIMT at CCA (p-trend=0.01) or 
7.3% lower cIMT max (p-trend=0.003), while the highest quintile of apoA-I with apoC-III 
was associated with 4.4% higher cIMT at CCA (p-trend=0.001) or 7.9% higher cIMT max 
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(p-trend=0.002). Total apoA-I was not significantly associated with either cIMT indexes (p-
trend>0.5), whereas higher levels of total apoC-III and apoC-III contained in HDL were 
significantly associated with higher cIMT (p-trend<0.01) 
 
Interpretation 
Both the concentration of HDL that has apoC-III and the concentration of apoC-III itself in 
HDL were associated with greater atherosclerosis in the carotid artery. ApoC-III-based HDL 
subspecies may be more informative than total HDL in distinguishing HDL functions and 
support the potential of HDL apoC-III as a promising target for atherosclerosis prevention 
and treatment. 
  
61 
 
 
INTRODUCTION  
A low level of HDL cholesterol or apolipoprotein A-I is a major risk factor for 
atherosclerotic cardiovascular diseases (1-4). However, the atheroprotective effect of HDL 
cholesterol is challenged by genetic studies and pharmaceutical trials, which do not support 
the causal relationship between increased HDL cholesterol levels and CVD. These findings 
suggest that HDL cholesterol might not fully capture the anti-atherogenic functions of HDL.  
The protein component of HDL rather than the cholesterol content of HDL might be 
more informative in explaining HDL functions because properties of these proteins can 
modify the functions of HDL. We recently found that HDL exists in subspecies based on the 
content of a small protein called apolipoprotein C-III (apoC-III). ApoC-III resides on the 
surface of lipoprotein particles and is shown to provoke inflammatory and atherogenic 
responses in monocytes and endothelial cells (5). Reilly and colleagues reported that apoC-III 
was associated with coronary artery calcification (CAC), a measure of asymptomatic 
atherosclerosis, in a cross-sectional study of persons with type 2 diabetes (11). About 6-7% of 
the total plasma apoA-I, the main HDL apolipoprotein, has apoC-III in healthy people with 
normal body weight (6), while the remainder of apoA-I is free of apoC-III. The percentage of 
apoA-I HDL that contains apoC-III in people with obesity is about 13-14%, which is double 
that of normal weight individuals (6). Furthermore, HDL with and without apoC-III 
demonstrated opposite associations with CHD risk in two prospective cohorts; HDL without 
apoC-III was associated with decreased risk of CHD, whereas HDL with apoC-III was 
associated with increased risk of CHD (7).  
Carotid intima-media thickness (cIMT) is a marker for early stage atherosclerosis (8) 
that is associated with cardiovascular risk factors (9) and cardiovascular outcomes (10). In 
this paper, we investigated how apoC-III-based HDL subspecies are associated with 
subclinical carotid atherosclerosis assessed as cIMT in a European multi-center study. We 
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hypothesized that HDL with apoC-III would be positively associated with cIMT, while HDL 
without apoC-III would be inversely associated with cIMT. We also studied apoB (includes 
LDL and VLDL lipoproteins) subspecies based on the presence of apoC-III. Based on a 
previous study (12), we hypothesized that apoB lipoproteins without apoC-III would be 
positively associated with cIMT but that associations for apoB with apoC-III would be even 
stronger.  
 
MATERIALS AND METHODS 
Study design and participants 
RISC is a European multi-center prospective cohort study with a standardized 
protocol and a centralized evaluation of measures (13). Healthy men and women ages 30-60 
(n=1,513) were recruited between June 2002 and July 2004, from the local population at 19 
centers in 14 European countries (Austria, Denmark, Finland, France, Germany, Greece, The 
Netherlands, Ireland, Italy, Sweden, Spain, Switzerland, United Kingdom and Serbia and 
Montenegro). Follow-up examinations were performed after 3 years. Exclusion criteria were 
treatment for any chronic disease, pregnancy, any cardiovascular event, weight change of ≥5 
kg in the last 3 months, cancer in the last 5 years, and renal or liver failure, recent major 
surgery, seizure disorder or epilepsy, arterial blood pressure ≥140/90 mmHg, fasting plasma 
glucose ≥7.0 mmol/L (126 mg/dl), 2-hour plasma glucose (on a standard 75-g OGTT) ≥11.0 
mmol/L (200 mg/dl), total serum cholesterol ≥7.8 mmol/L (300 mg/dl), serum triglycerides 
≥4.6 mmol/L (400 mg/dl), electrocardiogram abnormalities or acute myocardial ischemia 
injury or pericarditis. Out of 1,017 eligible subjects who had several biomarkers measured by 
the RISC investigators, baseline plasma samples of 987 subjects, which had enough plasma 
left for our experiment, were sent to our laboratory.  Each recruiting center obtained 
approval from local ethics committee. 
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Exposure assessment 
Information on basic characteristics of the participants including demographics (age, 
sex) and lifestyle (smoking, alcohol consumption, physical activity based on the International 
Physical Activity Questionnaire (IPAQ) score) were collected by interviews and 
questionnaires. Anthropometric measures and lipid levels (LDL-, HDL-, total-cholesterol and 
triglycerides) were also measured (13). 
We used a novel sandwich ELISA that we recently developed to measure the 
concentrations of total apoC-III, apoA-I in HDL without apoC-III, apoA-I in HDL with 
apoC-III; and the concentrations of apoB in lipoproteins with and without apoC-III 
(Yamamoto et al 2015, submitted). Briefly, a 96-well microplate coated with anti-human 
apoC-III antibody captured plasma lipoproteins that contained apoC-III. The unbound 
fraction was transferred to another plate coated with anti-human apoA-I antibody to measure 
the concentration of apoA-I that was not associated with apoC-III. The lipoproteins bound to 
the anti-apoC-III plate were dissociated with Tween-20, and then transferred to a plate coated 
with anti-human apoA-I antibody to measure the concentration of apoA-I that contained 
apoC-III. Total apoA-I was calculated as the sum of the concentrations of apoA-I with and 
without apoC-III. The concentrations of apoB with and without apoC-III were measured by 
applying the same principle for the apoA-I subspecies.  
For the measurement of apoC-III in HDL, whole plasma was precipitated with reagent 
to remove apoB-containing lipoproteins, and the apoC-III concentration in the remaining 
fraction was measured by standard sandwich ELISA. ApoC-III in HDL is different from 
apoA-I with apoC-III; the former represents the concentration of apoC-III itself contained in 
HDL whereas the latter represents the concentration of apoA-I in HDL with any amount of 
apoC-III. The apoC-III to apoA-I molar ratio, which may be interpreted as the density of 
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apoC-III on apoC-III-containing HDL, was calculated as the number of apoC-III molecules 
per apoA-I molecule on HDL particles containing apoC-III.  
Apolipoprotein measurements were corrected for batch variability using methods 
developed by Rosner et al (14). Age, sex, center, alcohol, smoking, physical activity and BMI 
were included in the regression for the Rosner correction method and were chosen based on 
the association with the exposure and the outcome. 
 
Outcome assessment 
Carotid images were obtained in each center by B-mode high-resolution 
ultrasonography, with the participant supine with neck slightly extended and head rotated 
contralaterally to the side. Longitudinal B-mode image was obtained of the distal 10 mm of 
right and left common carotid arteries, carotid bifurcation, and internal carotid artery from 
anterior, lateral and posterior angles. cIMT reading was performed in a centralized center 
(Pisa) by a single reader blinded to clinical data. cIMT was measured by bow compasses in 
digitized zoomed diastolic frames of each carotid segment at 5 different points and the 
average was calculated for each segment. For statistical analysis, cIMT at CCA was 
calculated as the mean of each CCA segment. cIMT max is the maximum cIMT in any 
carotid segment.  
As cIMT changes vary little over a short time, we treated the cIMT measures from 
baseline and year 3 as repeats and calculated their average to obtain most stable estimates of 
cIMT in a cross-sectional analysis. Additionally, we created a composite index by averaging 
cIMT at CCA and cIMT max.   
 
Statistical analysis  
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Baseline characteristics of participants were described in men and women separately 
using medians for continuous variables and percentages for categorical variables.  
The top and bottom 2% of the apolipoprotein exposures were trimmed to minimize 
the influence of outliers (n=40 removed). Observations that were missing outcome 
measurements, cIMT at CCA or cIMT max at baseline were deleted (n=83 removed).  We 
used the extreme studentized deviate (ESD) procedure to identify and exclude outliers (15, 
16) (n=15 removed) and excluded observations with residuals larger than 4 standard 
deviation (SD) (n=2 removed). The final sample size was 847. 
Linear regressions were performed to evaluate the relationships between 
apolipoprotein variables and outcomes. All outcome variables were log-transformed to 
improve normality. Sex-specific quintiles and quintile medians were created for each 
apolipoprotein variable, as the baseline apolipoprotein levels were different between men and 
women. Tests for trend were based on quintile medians. Nonlinearity was assessed with 
likelihood-ratio tests, comparing a model treating quintile medians continuously to a model 
with quintile indicators. In case there were no deviations from linearity (p for nonlinearity > 
0.05), we also created sex-specific z-scores to analyze associations per SD. We back-
transformed the coefficients to present results as the percent (%) difference in cIMT outcome 
per each SD higher or for each quintile compared with the lowest quintile. Potential 
confounders were selected based on our a priori knowledge as to the associations with the 
apolipoproteins as well as their effect on cIMT. Multivariable models were adjusted for age, 
sex, center, smoking (never; past; current smoker 1 to 14.9 or ≥15 tobacco grams per day), 
alcohol consumption (women: 0, 0.1 to 4.9, 5.0 to 14.9, or ≥15.0 g per day; men: 0, 0.1 to 
4.9, 5.0 to 29.9, or ≥30.0 g per day), physical activity (inactive; minimally active; highly 
active; or not reported) and BMI (continuous). Because apoA-I with and without apoC-III 
represent fractions of total apoA-I, the two apoA-I subspecies were entered in the model 
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simultaneously. Likewise, both apoB with and without apoC-III were included in the models 
for apoB lipoproteins. Likelihood ratio tests were performed based on linear trends to assess 
whether associations varied significantly for apoC-III-based subspecies. A model for apoC-
III in HDL was adjusted for total apoA-I. Finally, multivariable models were adjusted for 
triglycerides in the additional analysis.  
 
RESULTS 
Study participant characteristics 
The median age of study participants was 43 for men and 45 for women, and the 
median BMI was 26 kg/m2 for men and 24 kg/m2 for women. In general, participants had 
healthy lipid profiles with high HDL cholesterol (median for men: 1.2 mmol/l, women: 1.5 
mmol/l) and low LDL cholesterol (median for men: 3.0 mmol/l, women: 2.8 mmol/l) and 
triglycerides (median for men: 1.1 mmol/l, women: 0.9 mmol/l) (Table 3-1). cIMT values did 
not substantially change over the 3-year follow-up period. Median cIMT at CCA changed 
from 0.61 mm to 0.62 mm in men and from 0. 59 mm to 0.60 mm in women, and median 
cIMT max remained at 0.93 mm in men and changed from 0.88 mm to 0.90 mm in women. 
 
Associations between apolipoprotein A-I concentrations and cIMT 
ApoA-I in HDL with and without apoC-III demonstrated significantly opposite 
associations with both cIMT indexes in multivariable-adjusted models (p-heterogeneity of 
associations comparing the two subtypes was 0.002 for cIMT at CCA and 0.006 for cIMT 
max) (Figure 3-1). Compared to the lowest quintile, the highest quintile of apoA-I without 
apoC-III was associated with 3.7% lower cIMT at CCA (p-trend=0.01) or 7.3% lower cIMT 
max (p-trend=0.003), while the highest quintile of apoA-I with apoC-III was associated with 
4.4% higher cIMT at CCA (p-trend=0.001) or 7.9% higher cIMT max (p-trend=0.002) (Table 
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3-2). Total apoA-I was not significantly associated with either cIMT indexes (p-trend>0.5). 
These observations were consistent with the per SD analysis. Each SD higher apoA-I without 
apoC-III (= 18 mg/dL for men and 20 mg/dL for women) was associated with 1.0% lower 
cIMT at CCA (95% CI: -1.9, -0.1%) or 2.1% lower cIMT max (95% CI: -3.8, -0.4%), while 
each SD higher apoA-I with apoC-III (= 2.5 mg/dL for men and 2.6 mg/dL for women) was 
associated with 1.5% higher cIMT at CCA (95% CI: 0.6, 2.4%) or 2.2% higher cIMT max 
(95% CI: 0.5, 4.0%). These associations were confirmed when the composite cIMT was used 
as outcome (Figure 3-1C, Table 3-2). After additional adjustment of triglycerides in the 
multivariate model, the associations were attenuated but apoA-I with and without apoC-III 
still demonstrated significantly opposite associations with all cIMT indexes (Supplementary 
Table 3-1).  
 
Associations between apolipoprotein C-III concentrations and cIMT     
ApoC-III concentration in HDL was associated with higher cIMT. The highest 
quintile of apoC-III in HDL was associated with 4.6% higher cIMT at CCA (p-trend=0.0003) 
or 5.9% higher cIMT max (p-trend=0.02) as compared to the lowest quintile (Figure 3-2, 
Table 3-3). These significant associations persisted even after adjusting for triglycerides. 
Total apoC-III was also associated with cIMT at CCA (p-trend=0.02) and composite cIMT 
(p-trend=0.045). However, after additionally adjusting for triglycerides, these associations 
became null (Supplementary Table 3-2). The apoC-III to apoA-I molar ratio was not 
associated with any of cIMT indexes. All the above findings were consistent between the 
quintile analysis and per SD analysis. 
 
ApoB subspecies concentrations 
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Total apoB was associated with higher cIMT. The highest quintile had 3.3% higher 
cIMT at CCA (p-trend=0.004) or 4.3% higher cIMT max (p-trend=0.047). Although the 
associations were not as strong and consistent as those of total apoB, apoB without apoC-III 
was also associated with cIMT at CCA and the composite cIMT, especially in the per SD 
analysis. No such associations were present for apoB with apoC-III (Table 3-4).  
 
DISCUSSION 
The present study showed that two HDL subspecies, HDL with and without apoC-III, 
have significantly opposite associations with cIMT. We found that apoA-I without apoC-III 
was associated with lower cIMT, whereas apoA-I with apoC-III was associated with higher 
cIMT. These findings pertaining to apoC-III-containing HDL are strengthened by our 
findings on apoC-III in HDL, which was positively associated with cIMT, because it 
reiterates that the apoC-III component of HDL is crucial in determining the association of 
HDL with cIMT. This and previous research indicate that the concept of HDL subspecies 
based on the presence or absence of apoC-III may have implications for metabolic conditions 
and CHD risk (6, 7). 
We did not observe an association between total HDL levels, reflected by measures of 
plasma total apoA-I, and cIMT. This is in agreement with previous studies which reported 
that low HDL cholesterol levels due to mutations in ABCA1, APOAI and LCAT were not 
associated with increased cIMT and high HDL cholesterol levels due to CETP deficiency 
were not associated with cIMT (17). Results of observational studies are also conflicting with 
regard to the association between HDL cholesterol and cIMT (18). The Carotid 
Atherosclerosis Progression Study among 3,383 participants reported that HDL cholesterol 
levels were not associated with any of cIMT measured at CCA, internal carotid artery and 
carotid bifurcation (19). In Multi-Ethnic Study of Atherosclerosis (MESA) study with 4,792 
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participants, low HDL cholesterol levels were significantly associated with cIMT max but not 
with cIMT measured at internal carotid artery (20).  
There are a few potential mechanisms through which apoC-III may render HDL 
proatherogenic. Studies in cells and animal models have shown that apoC-III increases 
cytokine expression in cultured monocytes and endothelial cells (5, 21, 22). HDL without 
apoC-III decreased the proinflammatory adhesion of human monocytes to endothelial cells, 
whereas HDL with apoC-III did not (21). ApoC-III inhibits clearance of plasma VLDL and 
LDL by the liver (23-26). ApoC-III may similarly affect the circulation of HDL and its 
delivery to the liver. However, this needs to be confirmed by kinetics studies to compare the 
catabolism of HDL with and without apoC-III. We also speculate that apoC-III may interfere 
with the cholesterol efflux capacity of HDL. In two distinct cohorts of 996 patients, 
cholesterol efflux capacity was inversely associated with cIMT independently of HDL 
cholesterol and apoA-I levels (27). Interestingly, HDL cholesterol was significantly 
associated with cholesterol efflux capacity but was not associated with cIMT. It would be 
interesting to perform cholesterol efflux assay using HDL separated based on the presence of 
apoC-III and investigate if HDL subspecies have differential effects on cholesterol efflux. 
The results for apoB-lipoprotein subspecies were not significant. This might be 
because apoB-containing lipoproteins in this study contained both LDL and VLDL instead of 
only LDL. Mendivil et al showed that apoB in LDL with apoC-III was associated with 
increased risk of CHD, whereas the association between apoB in LDL without apoC-III and 
CHD risk was null (12). The same study showed no differential effects by VLDL subspecies, 
with both apoB in VLDL with and without apoC-III being associated with increased risk of 
CHD. In contrast, Lee et al 2003 showed that the apoB concentration of VLDL with apoC-III 
was associated with decreased risk for recurrent coronary events among diabetic patients, 
while VLDL without apoC-III was associated with increased risk (28). Taken together, these 
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results suggest a need to look at LDL and VLDL separately when examining their apoC-III 
defined subspecies with the risk of CHD. 
There are several strengths in our study. First, as we used replicated measurements for 
cIMT outcome values, measurement errors were reduced. Since the measurement errors were 
most likely non-differential, the effect estimates became more precise. Second, cIMT was 
measured in two different ways, cIMT at CCA and cIMT max. We also created a composite 
index of the two. We were able to confirm consistent results overall across the three cIMT 
indexes. Third, the modified sandwich ELISA method has relatively low intra-assay and 
inter-assay variability compared to other methods such as immuno-affinity chromatography 
(Yamamoto et al 2015, submitting). Finally, since all assays for apolipoprotein exposures and 
cIMT reading were performed by one analyst each, there was no inter-rater variability.  
One limitation of this study is the cross-sectional nature of analysis and therefore the 
temporality of the associations could not be established. Another limitation is the variation 
across study sites due to the multi-center design of the RISC study. However, the exposure 
measurement was performed independently of the outcome assessment and blinded to the 
outcome status. Therefore, it is likely that the variation was non-differential and the effect 
estimates were pulled toward the null. Finally, the generalizability of the study was limited 
since the participants were all Europeans. Future studies using cohorts with different ethnic 
compositions are needed for improved generalizability.  
In conclusion, in the analysis of healthy men and women in the RISC cohort, two 
HDL subspecies had significantly opposite associations with cIMT, with HDL with apoC-III 
being associated with higher cIMT and HDL without apoC-III associated with lower cIMT. 
In addition, the concentration of apoC-III contained in HDL was associated with higher 
cIMT. Our results support the potential of HDL apoC-III as a promising target for 
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atherosclerosis prevention and treatment and have implications for a refined approach based 
on apoC-III content of future therapeutic targets for cardiovascular prevention. 
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Table 3-1. Baseline characteristics of men and women in the RISC study included in this 
study 
Tables 
 
BMI=body mass index, BP=blood pressure, IPAQ=international physical activity questionnaire, cIMT 
at CCA=carotid intima-media thickness at common carotid artery, cIMT max=the maximum carotid 
intima-media thickness, FFM=fat free mass, HDL-C= HDL Cholesterol, LDL-C=LDL Cholesterol, 
TG=triglyceride, FFA=free fatty acid, ApoA-I without apoC-III=the concentration of apoA-I in HDL 
that does not contain apoC-III, ApoA-I with apoC-III=the concentration of apoA-I in HDL that contains 
apoC-III, % of apoA-I with apoC-III=% of apoA-I in HDL that contains apoC-III, ApoB without apoC-
III=the concentration of apoB in LDL and VLDL that does not contain apoC-III, ApoB with apoC-
  
Men (N=369) Women (N=478) 
Median 
25th, 75th 
percentile 
Median 
25th, 75th 
percentile 
Age, yrs 43 (36, 51) 45 (39, 51) 
BMI, kg/m2 26 (24, 28) 24 (22, 27) 
Systolic BP, mmHg 122 (115, 130) 115 (106, 123) 
Diastolic BP, mmHg 77 (71, 81) 73 (67, 79) 
IPAQ, % 
(inactive/moderate/active) 
19/42/39, % 19/43/37, % 
Alcohol, g/wk 77 (38, 143) 30 (11, 65) 
Smoker, % 
(never/current/ex) 
47/27/26, % 47/25/28, % 
Menopause, % - 26% 
Average of cIMT at CCA, mm 0.61 (0.56, 0.67) 0.59 (0.54, 0.65) 
cIMT at CCA (baseline), mm 0.61 (0.56, 0.66) 0.59 (0.53, 0.64) 
cIMT at CCA (year 3), mm 0.62 (0.57, 0.69) 0.60 (0.56, 0.66) 
Average of cIMT max, mm 0.94 (0.84, 1.11) 0.89 (0.80, 1.05) 
cIMT max (baseline), mm 0.93 (0.83, 1.11) 0.88 (0.78, 1.07) 
cIMT max (year 3), mm 0.93 (0.82, 1.13) 0.90 (0.80, 1.05) 
Adiponectin, mg/l 6 (5, 8) 9 (7, 12) 
Leptin, ng/ml 5 (2, 8) 15 (10, 24) 
Cholesterol, mmol/l 4.9 (4.3, 5.5) 4.8 (4.3, 5.4) 
HDL-C, mmol/l 1.2 (1.1, 1.4) 1.5 (1.4, 1.8) 
LDL-C, mmol/l 3.0 (2.6, 3.6) 2.8 (2.3, 3.3) 
TG, mmol/l 1.1 (0.8, 1.5) 0.9 (0.6, 1.1) 
FFA, mmol/l 0.43 (0.35, 0.57) 0.56 (0.45, 0.71) 
ApoA-I without apoC-III, 
mg/dl 
90 (79, 102) 103 (90, 117) 
ApoA-I with apoC-III, mg/dl 7.4 (6.1, 8.9) 8.4 (7.0, 10.1) 
% of apoA-I with apoC-III, % 7.6 (6.5, 8.9) 7.6 (6.6, 8.8) 
ApoB without apoC-III, mg/dl 71 (61, 86) 67 (55, 80) 
ApoB with apoC-III, mg/dl 4.3 (3.3, 5.5) 4.0 (3.1, 5.0) 
% of apoB with apoC-III, % 5.6 (4.6, 6.9) 5.8 (4.7, 7.0) 
ApoC-III, mg/dl 9.9 (7.7, 12.8) 9.8 (7.6, 12.3) 
ApoC-III in HDL, mg/dl 5.8 (4.7, 7.7) 5.6 (4.6, 6.9) 
ApoC-III in apoB, mg/dl 4.2 (2.8, 6.0) 4.2 (2.8, 5.7) 
ApoC-III : ApoA-I molar ratio 2.6 (2.2, 3.1) 2.2 (1.9, 2.6) 
ApoC-III : ApoB molar ratio 61 (43, 80) 62 (47, 84) 
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III=the concentration of apoB in LDL and VLDL that contains apoC-III, % of apoB with apoC-III=% 
of apoB in LDL and VLDL that contains apoC-III, ApoC-III in HDL=the concentration of apoC-III 
contained in HDL fraction, ApoC-III in apoB=the concentration of apoC-III contained in LDL and 
VLDL, ApoC-III : ApoA-I molar ratio= the molar ratio of apoC-III to apoA-I in apoC-III-containing 
HDL, ApoC-III : ApoB molar ratio= the molar ratio of apoC-III to apoB in apoC-III-containing LDL 
and VLDL    
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Table 3-2. Association between apoA-I concentrations and cIMT 
 
Outcome Exposure 
Quintiles 
P-trend per-SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
cIMT at CCA 
Total apoA-I 0% -0.3% 0.82 1.5% 0.22 -0.1% 0.94 -0.6% 0.59 0.70 0.0% 0.90 
ApoA-I without apoC-III 0% -1.5% 0.18 0.4% 0.72 -1.7% 0.17 -3.7% 0.005 0.01 -1.0% 0.02 
ApoA-I with apoC-III 0% 0.6% 0.60 2.9% 0.02 2.8% 0.02 4.4% 0.001 0.001 1.5% 0.001 
cIMT max 
Total apoA-I 0% -1.0% 0.63 2.2% 0.32 1.0% 0.64 -1.9% 0.40 0.58 -0.5% 0.49 
ApoA-I without apoC-III 0% -1.0% 0.64 -0.7% 0.75 -2.1% 0.36 -7.3% 0.003 0.003 -2.1% 0.02 
ApoA-I with apoC-III 0% -0.6% 0.79 6.3% 0.01 3.1% 0.19 7.9% 0.003 0.002 2.2% 0.01 
composite cIMT 
Total apoA-I 0% -0.8% 0.63 1.9% 0.26 0.5% 0.76 -1.4% 0.39 0.56 -0.3% 0.52 
ApoA-I without apoC-III 0% -1.2% 0.47 -0.4% 0.82 -2.0% 0.25 -6.0% 0.001 0.002 -1.7% 0.009 
ApoA-I with apoC-III 0% -0.2% 0.89 5.0% 0.004 2.9% 0.10 6.5% 0.001 0.0004 1.9% 0.003 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI. Analysis of apoA-I without and with apoC-
III simultaneously adjusted.   
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Table 3-3. Association between apoC-III concentrations and cIMT 
 
Outcome Exposure 
Quintiles 
P-trend per-SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
cIMT at CCA 
Total apoC-III 0% 0.6% 0.60 1.0% 0.39 2.4% 0.04 2.2% 0.06 0.02 1.2% 0.002 
ApoC-III in HDL 0% 1.4% 0.22 2.1% 0.07 3.2% 0.01 4.6% 0.0003 0.0003 1.6% 0.0001 
ApoC-III to apoA-I ratio 0% 3.1% 0.01 2.7% 0.02 2.7% 0.03 2.7% 0.03 0.10 0.6% 0.11 
cIMT max 
Total apoC-III 0% 2.2% 0.33 3.4% 0.13 5.1% 0.02 3.4% 0.14 0.10 1.1% 0.13 
ApoC-III in HDL 0% 1.0% 0.66 3.4% 0.14 5.4% 0.02 5.9% 0.02 0.007 1.6% 0.03 
ApoC-III to apoA-I ratio 0% 3.0% 0.18 4.3% 0.07 0.6% 0.78 1.5% 0.54 0.99 0.5% 0.48 
composite cIMT 
Total apoC-III 0% 1.4% 0.39 2.4% 0.14 4.1% 0.02 2.9% 0.08 0.045 1.1% 0.04 
ApoC-III in HDL 0% 1.1% 0.51 2.9% 0.09 4.5% 0.01 5.4% 0.003 0.001 1.6% 0.005 
ApoC-III to apoA-I ratio 0% 2.9% 0.08 3.7% 0.03 1.4% 0.40 1.9% 0.28 0.66 0.6% 0.31 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI.   
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Table 3-4. Association between apoB concentrations and cIMT 
 
Outcome Exposure 
Quintiles 
P-trend per-SD 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p % difference p 
cIMT at CCA 
Total apoB 0% 1.2% 0.32 2.1% 0.07 2.6% 0.03 3.3% 0.01 0.004 1.4% 
0.000
3 
ApoB without apoC-III 0% 1.8% 0.13 1.6% 0.21 1.9% 0.13 2.7% 0.06 0.07 1.3% 0.004 
ApoB with apoC-III 0% -1.6% 0.18 -0.9% 0.44 1.8% 0.16 0.1% 0.96 0.37 0.1% 0.76 
cIMT max 
Total apoB 0% 1.7% 0.45 2.8% 0.21 3.6% 0.12 4.3% 0.07 0.047 1.7% 0.02 
ApoB without apoC-III 0% -0.7% 0.74 2.7% 0.26 1.9% 0.44 0.5% 0.85 0.60 1.1% 0.19 
ApoB with apoC-III 0% -1.9% 0.40 1.1% 0.64 3.1% 0.21 2.1% 0.42 0.18 1.0% 0.23 
composite cIMT 
Total apoB 0% 1.4% 0.40 2.4% 0.14 3.2% 0.06 4.0% 0.02 0.01 1.6% 0.004 
ApoB without apoC-III 0% 0.1% 0.95 2.2% 0.22 1.9% 0.30 1.3% 0.51 0.34 1.2% 0.06 
ApoB with apoC-III 0% -1.9% 0.26 0.2% 0.89 2.6% 0.15 1.3% 0.52 0.18 0.7% 0.29 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity and BMI. Analysis of apoB without and with apoC-III 
simultaneously adjusted.   
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Supplementary Table 3-1. Association between apoA-I concentrations and cIMT after adjusting for TG 
 
Outcome Exposure 
Quintiles 
P-trend per-SD 
Q1 Q2 Q3 Q4 Q5 
ref 
%  
difference 
p 
% 
 difference 
p 
%  
difference 
p 
%  
difference 
p p 
%  
difference 
p 
cIMT at CCA 
Total apoA-I 0% -0.3% 0.77 1.8% 0.12 -0.1% 0.94 -0.5% 0.66 0.77 0.0% 0.94 
ApoA-I without apoC-III 0% -1.3% 0.25 0.8% 0.49 -1.2% 0.35 -3.0% 0.03 0.06 -0.8% 0.11 
ApoA-I with apoC-III 0% 0.3% 0.80 2.3% 0.06 2.2% 0.08 3.2% 0.03 0.02 1.1% 0.03 
cIMT max 
Total apoA-I 0% -1.1% 0.62 2.4% 0.28 1.1% 0.62 -1.8% 0.42 0.60 -0.5% 0.49 
ApoA-I without apoC-III 0% -1.0% 0.63 -0.8% 0.72 -2.1% 0.38 -7.4% 0.003 0.004 -2.1% 0.02 
ApoA-I with apoC-III 0% -0.5% 0.81 6.3% 0.009 3.2% 0.18 7.9% 0.005 0.003 2.2% 0.02 
composite cIMT 
Total apoA-I 0% -0.8% 0.61 2.1% 0.20 0.6% 0.74 -1.3% 0.42 0.59 -0.3% 0.52 
ApoA-I without apoC-III 0% -1.1% 0.50 -0.3% 0.86 -1.8% 0.31 -5.8% 0.002 0.004 -1.6% 0.02 
ApoA-I with apoC-III 0% -0.3% 0.84 4.8% 0.007 2.8% 0.12 6.1% 0.003 0.002 1.8% 0.01 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity, BMI and TG. Analysis of apoA-I without and with 
apoC-III simultaneously adjusted.  
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Supplementary Table 3-2. Association between apoC-III concentrations and cIMT after adjusting for TG 
 
Outcome Exposure 
Quintiles 
P-trend z-score 
Q1 Q2 Q3 Q4 Q5 
ref 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p 
% 
difference 
p p 
% 
difference 
p 
cIMT at CCA 
Total apoC-III 0% 0.3% 0.79 0.4% 0.76 1.7% 0.17 0.3% 0.82 0.58 0.7% 0.14 
ApoC-III in HDL 0% 1.2% 0.31 1.7% 0.16 2.6% 0.05 3.3% 0.03 0.03 1.3% 0.02 
ApoC-III to apoA-I ratio 0% 2.7% 0.02 2.3% 0.06 1.9% 0.13 1.2% 0.40 0.76 0.0% 0.94 
cIMT max 
Total apoC-III 0% 1.9% 0.38 3.0% 0.18 4.9% 0.04 2.5% 0.35 0.23 0.9% 0.32 
ApoC-III in HDL 0% 1.2% 0.61 3.7% 0.11 5.9% 0.02 6.6% 0.03 0.009 2.1% 0.05 
ApoC-III to apoA-I ratio 0% 2.7% 0.23 4.0% 0.09 0.0% 0.99 0.1% 0.96 0.58 0.2% 0.83 
composite cIMT 
Total apoC-III 0% 1.2% 0.48 1.9% 0.25 3.6% 0.04 1.7% 0.40 0.24 0.8% 0.21 
ApoC-III in HDL 0% 1.1% 0.50 2.9% 0.09 4.6% 0.01 5.4% 0.01 0.005 1.8% 0.02 
ApoC-III to apoA-I ratio 0% 2.7% 0.12 3.4% 0.05 0.7% 0.68 0.5% 0.79 0.72 0.1% 0.84 
 
Multivariable linear regression models adjusted for age, sex, center, alcohol, smoking, physical activity, BMI and TG. 
  
82 
 
 
Figure 3-1. Association between apoA-I concentrations and cIMT 
Figures 
   
 
 
   
Multivariable linear regression models adjusted for age, sex, 
center, alcohol, smoking, physical activity and BMI. Analysis 
of apoA-I without and with apoC-III simultaneously adjusted.  
P-heterogeneity in panels comparing trends across quintiles of 
apoA-I with and without apoC-III. 
(A) 
(B) 
(C) 
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Figure 3-2. Association between apoC-III concentrations and cIMT 
 
  
 
   
Multivariable linear regression models adjusted for age, sex, 
center, alcohol, smoking, physical activity and BMI.  
 
(A) (B) 
(C) 
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